<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis - Hurley, MN - 2020 | Cochrane Library</title> <meta content="Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis - Hurley, MN - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008037.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis - Hurley, MN - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008037.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008037.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis" name="citation_title"/> <meta content="Matthew N Hurley" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Matthew.hurley@nuh.nhs.uk" name="citation_author_email"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Douglas L Forrester" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Alan R Smyth" name="citation_author"/> <meta content="School of Medicine, University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008037.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008037.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008037.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008037.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [*administration &amp; dosage]; Antibodies, Monoclonal [therapeutic use]; Bacterial Infections [*drug therapy, microbiology]; beta Carotene [therapeutic use]; Chemotherapy, Adjuvant; Cystic Fibrosis [*complications]; Disease Progression; Garlic; Immunoglobulin Fab Fragments [therapeutic use]; Lung Diseases [*drug therapy, microbiology]; Nitric Oxide [therapeutic use]; Pseudomonas aeruginosa; Pseudomonas Infections [drug therapy]; Randomized Controlled Trials as Topic; Vitamins [therapeutic use]; Zinc [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008037.pub4&amp;doi=10.1002/14651858.CD008037.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008037\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008037\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008037.pub4",title:"Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis",firstPublishedDate:"Jul 16, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008037.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008037.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008037.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008037.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008037.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008037.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008037.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008037.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008037.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008037.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4759 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008037.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/appendices#CD008037-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/table_n/CD008037StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/table_n/CD008037StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#CD008037-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Matthew N Hurley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#CD008037-cr-0005">Sherie Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#CD008037-cr-0006">Douglas L Forrester</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information#CD008037-cr-0007">Alan R Smyth</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information/en#CD008037-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008037.pub4">https://doi.org/10.1002/14651858.CD008037.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008037-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008037-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008037-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008037-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008037-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008037-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008037-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008037-abs-0001" lang="en"> <section id="CD008037-sec-0001"> <h3 class="title" id="CD008037-sec-0001">Background</h3> <p>Cystic fibrosis is a multi‐system disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. This leads to lung destruction and eventually death through respiratory failure. There are no antibiotics in development that exert a new mode of action and many of the current antibiotics are ineffective in eradicating the bacteria once chronic infection is established. Antibiotic adjuvants ‐ therapies that act by rendering the organism more susceptible to attack by antibiotics or the host immune system, by rendering it less virulent or killing it by other means, would be a significant therapeutic advance. This is an update of a previously published review. </p> </section> <section id="CD008037-sec-0002"> <h3 class="title" id="CD008037-sec-0002">Objectives</h3> <p>To determine if antibiotic adjuvants improve clinical and microbiological outcome of pulmonary infection in people with cystic fibrosis. </p> </section> <section id="CD008037-sec-0003"> <h3 class="title" id="CD008037-sec-0003">Search methods</h3> <p>We searched the Cystic Fibrosis Trials Register which is compiled from database searches, hand searches of appropriate journals and conference proceedings. </p> <p>Date of most recent search: 16 January 2020.</p> <p>We also searched MEDLINE (all years) on 14 February 2019 and ongoing trials registers on 06 April 2020. </p> </section> <section id="CD008037-sec-0004"> <h3 class="title" id="CD008037-sec-0004">Selection criteria</h3> <p>Randomised controlled trials and quasi‐randomised controlled trials of a therapy exerting an antibiotic adjuvant mechanism of action compared to placebo or no therapy for people with cystic fibrosis. </p> </section> <section id="CD008037-sec-0005"> <h3 class="title" id="CD008037-sec-0005">Data collection and analysis</h3> <p>Two of the authors independently assessed and extracted data from identified trials.</p> </section> <section id="CD008037-sec-0006"> <h3 class="title" id="CD008037-sec-0006">Main results</h3> <p>We identified 42 trials of which eight (350 participants) that examined antibiotic adjuvant therapies are included. Two further trials are ongoing and five are awaiting classification. The included trials assessed β‐carotene (one trial, 24 participants), garlic (one trial, 34 participants), KB001‐A (a monoclonal antibody) (two trials, 196 participants), nitric oxide (two trials, 30 participants) and zinc supplementation (two trials, 66 participants). The zinc trials recruited children only, whereas the remaining trials recruited both adults and children. Three trials were located in Europe, one in Asia and four in the USA. </p> <p>Three of the interventions measured our primary outcome of pulmonary exacerbations (β‐carotene, mean difference (MD) ‐8.00 (95% confidence interval (CI) ‐18.78 to 2.78); KB001‐A, risk ratio (RR) 0.25 (95% CI 0.03 to 2.40); zinc supplementation, RR 1.85 (95% CI 0.65 to 5.26). β‐carotene and KB001‐A may make little or no difference to the number of exacerbations experienced (low‐quality evidence); whereas, given the moderate‐quality evidence we found that zinc probably makes no difference to this outcome. </p> <p>Respiratory function was measured in all of the included trials. β‐carotene and nitric oxide may make little or no difference to forced expiratory volume in one second (FEV<sub>1</sub>) (low‐quality evidence), whilst garlic probably makes little or no difference to FEV<sub>1</sub> (moderate‐quality evidence). It is uncertain whether zinc or KB001‐A improve FEV<sub>1</sub> as the certainty of this evidence is very low. </p> <p>Few adverse events were seen across all of the different interventions and the adverse events that were reported were mild or not treatment‐related (quality of the evidence ranged from very low to moderate). </p> <p>One of the trials (169 participants) comparing KB001‐A and placebo, reported on the time to the next course of antibiotics; results showed there is probably no difference between groups, HR 1.00 (95% CI 0.69 to 1.45) (moderate‐quality evidence). Quality of life was only reported in the two KB001‐A trials, which demonstrated that there may be little or no difference between KB001‐A and placebo (low‐quality evidence). Sputum microbiology was measured and reported for the trials of KB001‐A and nitric oxide (four trials). There was very low‐quality evidence of a numerical reduction in <i>Pseudomonas aeruginosa</i> density with KB001‐A, but it was not significant. The two trials looking at the effects of nitric oxide reported significant reductions in <i>Staphylococcus aureus</i> and near‐significant reductions in <i>Pseudomonas aeruginosa</i>, but the quality of this evidence is again very low. </p> </section> <section id="CD008037-sec-0007"> <h3 class="title" id="CD008037-sec-0007">Authors' conclusions</h3> <p>We could not identify an antibiotic adjuvant therapy that we could recommend for treating of lung infection in people with cystic fibrosis. The emergence of increasingly resistant bacteria makes the reliance on antibiotics alone challenging for cystic fibrosis teams. There is a need to explore alternative strategies, such as the use of adjuvant therapies. Further research is required to provide future therapeutic options. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008037-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008037-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008037-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008037-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008037-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008037-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008037-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008037-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008037-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008037-abs-0002" lang="en"> <h3>Antibiotic enhancing treatment for lung infections in cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the use of agents to help antibiotics in treating lung infections in people with cystic fibrosis. </p> <p><b>Background</b> </p> <p>People with cystic fibrosis suffer from infections in their lungs as they produce thick secretions which allow bacteria to grow in them. Often the infections are caused by unusual bacteria, including <i>Pseudomonas aeruginosa,</i> and these bacteria become resistant to treatment with antibiotics. Long‐term infection reduces a person's quality of life and their lung function. There are no new antibiotics currently being developed which use a new type of action. New agents ‐ antibiotic adjuvants ‐ are needed to work alongside antibiotics to make bacteria more sensitive to either antibiotics or to the body's own immune system, and to interfere with the formation of colonies of bacteria in the lungs. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 16 January 2020.</p> <p><b>Trial characteristics</b> </p> <p>The review includes eight trials with 350 people with cystic fibrosis aged between five and 54 years of age<i>.</i> Trials compared different antibiotic adjuvants (beta‐carotene (one trial), garlic (one trial), a biological agent (two trials), nitric oxide (two trials) and zinc (two trials)) with placebo (a substance that contains no medication) and people were selected for one treatment or the other randomly. The trials lasted from two days to one year. </p> <p><b>Key results</b> </p> <p>None of the treatments led to a longer time until the next flare up of lung disease compared to the people who received placebo. For the other measures we looked at (lung function, side effects, quality of life or number of infections) there were also no differences between the people given the adjuvant and the people given the placebo. All of the trials measured side effects of the treatment but these were mostly mild and happened in both the people receiving the treatment and those that did not. </p> <p>None of the therapies for enhancing the actions of antibiotics which we found, showed a significant benefit for either lung function, rate of infection or quality of life. More randomised controlled trials are needed before we can recommend the routine use of any of these therapies. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence ranges from very low to moderate, but we judged it to be low overall. We made these judgements because of the small number of trials that looked at each of the different adjuvant treatments meaning we were unable to combine results. The quality was also affected by the small number of people who were included. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008037-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008037-sec-0108"></div> <h3 class="title" id="CD008037-sec-0109">Implications for practice</h3> <section id="CD008037-sec-0109"> <p>Various strategies have been investigated in an attempt to improve the current position where individuals are infected with resistant bacteria for which no successful treatment is available. Unfortunately, however, trials of these strategies have been of poor quality and often limited to observational or limited cohort studies. The more rigorous trials have suffered from either a lack of statistical power or robust outcome measures. </p> <p>There continues to be no alternative to conventional antibiotics alone in the treatment of pulmonary infection in those with cystic fibrosis (CF). </p> </section> <h3 class="title" id="CD008037-sec-0110">Implications for research</h3> <section id="CD008037-sec-0110"> <p>Antibiotics remain the mainstay of treatment for pulmonary infection in CF. The emergence of increasingly‐resistant bacteria makes the reliance on antibiotics alone challenging for CF teams. There is a need to explore alternative strategies, such as the use of adjuvant therapies, that may prove a beneficial alternative. Novel strategies should aim to be founded on robust in vitro pre‐clinical development work that includes clinical isolates of mixed phenotypes of bacteria in models of infection that include both planktonic and biofilm modes of growth. Well‐designed placebo‐controlled double‐blind randomised trials of sufficient power and duration are required to determine the efficacy of any new strategy in both children and adults with CF. Such trials need to use outcome measures that are both objective and important to people with CF, specifically lung function, pulmonary exacerbation frequency, hospital attendance and measures of quality of life. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008037-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008037-sec-0008"></div> <div class="table" id="CD008037-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: oral β‐carotene supplementation </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>β‐carotene</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Days of antibiotic use</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of antibiotics was 18.5 days in the control group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of antibiotics in the intervention group was <b>8 days lower</b> (18.8 days lower to 2.78 days higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐8.00</b> (‐18.78 to 2.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of this paper defined pulmonary exacerbations by the number of days of antibiotics. </p> <p>Pulmonary exacerbations were less frequent in the intervention group but this was not statistically significant (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> absolute FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted was 80.9% in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was <b>10.9% lower</b> (32.2% lower to 10.4% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐10.90</b> (‐32.23 to 10.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results favour the placebo for effect on FEV<sub>1</sub> but this was not significant (P = 0.32). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no adverse events reported during the trial. Some participants reported better tanning after exposure to sunlight. No further data were provided for adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>see pulmonary exacerbations</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was reported by the authors as their definition of pulmonary exacerbations. The number of days of antibiotics was less in the β‐carotene group but not significantly so (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to risk of bias within the included trial, particularly from uncertainty of randomisation method and allocation concealment.<br/><sup>b</sup> Downgraded once due to imprecision. The trial had a small number of participants which is well below the optimal information size and low event rates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008037-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with <i>P aeruginosa</i> </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: garlic capsule once daily </p> <p><b>Comparison</b>: placebo capsule once daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Garlic supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> change from baseline in % predicted FEV<sub>1</sub> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted was ‐3.6 % in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>1.59% higher</b> (7.49% lower to 10.67% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.59</b> (‐7.49 to 10.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the groups after 8 weeks of treatment (P = 0.73). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>mild adverse events</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 participants in the garlic group reported minor adverse effects: diarrhoea: OR 5.87 (95% CI 0.25 to 135.15; P = 0.27); halitosis: OR 5.87 (95% CI 0.25 to 135.15; P = 0.27); abdominal pain: OR 3.24 (95% CI 0.12 to 87.13; P = 0.48); dysuria: OR 3.24 (95% CI 0.12 to 87.13; P = 0.48). </p> <p>1 participant in each group reported minor haemoptysis, OR 1.00 (95% CI 0.06 to 17.90; P = 1.0). </p> <p>Overall there was no significant difference between garlic and placebo for any of the adverse effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>days of antibiotic use</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days of antibiotic use was not reported but 7 participants in the garlic group received intravenous antibiotics compared to 5 in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision from low number of participants which does not reach the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008037-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (12 or over) and adults with cystic fibrosis and lung infection </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: monoclonal antibody KB001‐A </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>KB001‐A</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 8 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Of the 2 trials reporting this outcome, the small trial reported no pulmonary exacerbations in the low‐dose group (10 mg/kg), 1 pulmonary exacerbation in the 3 mg/kg group and 2 pulmonary exacerbations in the placebo group (RR 0.25 (95% CI 0.03 to 2.40)). This showed a slight difference in favour of KB001‐A but this was non‐significant (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>The larger Jain trial, did not report exacerbations as an outcome, but did report that exacerbations were the most commonly reported adverse event in both the KB001‐A and placebo group (57.8% of KB001‐A participants and 67.4% of placebo participants) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data from the 2 trials could not be combined as 1 was a single‐dose trial whilst the other trial administered KB001‐A via infusion every 4 weeks over 16 weeks in total. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>number of episodes of a drop in FEV<sub>1</sub> (unit of measurement not given) </p> <p>Follow‐up: 8 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Six participants who received a single 3 mg/kg dose of KB001‐A experienced a decrease in FEV<sub>1</sub>, RR 4.74 (95% CI 0.28 to 79.44) compared to no drop in FEV<sub>1</sub> in the placebo group (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>At the end of the 16‐week trial of KB001‐A, the authors reported a 3 percentage point increase from baseline in % predicted FEV<sub>1</sub>, MD 3.2% (95% CI 1.12% predicted to 5.30% predicted; P = 0.003) in the KB001‐A arm versus placebo (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>number of participants experiencing adverse events</p> <p>Follow up: 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla (single‐dose trial) reported a slight non‐significant difference in how many participants experienced any adverse event favouring placebo, RR 1.30 (95% CI 0.90 to 1.87) and no significant difference between intervention and placebo for serious adverse events: bronchitis (1 participant in the KB001‐A group) RR 1.58 (95% CI 0.07 to 35.32); sinusitis (1 participant in the placebo group) RR 0.18 (95% CI 0.01 to 3.92) (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain reported no treatment‐emergent adverse events and similar numbers of participants with infusion reactions between intervention and placebo groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the trials reported significant differences in any adverse events, but event rates were very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>time to need for antibiotics</p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Jain found no difference in the time to need for antibiotics in the KB001‐A group versus placebo over the 16‐week trial period, HR 1.00 (95% CI 0.69 to 1.45). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>change in CFQ‐R score</p> <p>Follow‐up: 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla reported no difference in the change in CFQ‐R from baseline between the KB001‐A and placebo groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only the Milla study reported CFQ‐R (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain (n = 169) did not measure CFQ‐R, but did measure change in respiratory symptom scores from baseline using the CFRSD‐CRISS symptom severity score. There was no difference found between treatment groups (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>We were not able to enter the data into the analysis and have reported results narratively (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). At day 28 there was a numerical reduction from baseline in median mucoid <i>P aeruginosa</i> density in the KB001‐A 10 mg/kg group (‐0.4 log<sub>10</sub>) compared to placebo (0.8 log<sub>10</sub>), but the changes were not significant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory markers</b> </p> <p>Follow‐up: 28 to 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla reported no significant change from baseline in any biomarkers but there was a trend towards a KB001‐A dose‐dependent reduction in sputum MPO, IL‐8, IL‐1β and NE (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain reported a ‐0.24 log<sub>10</sub> reduction in IL‐8 in the KB001‐A group compared to placebo at week 16 (P = 0.04) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Jain trial also reported a non‐significant decrease in sputum NE, MD ‐0.27 (95% CI ‐0.58 to 0.04; P = 0.084) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R</b> : CF Questionnaire‐Revised; <b>CFRSD‐CRISS</b> : Cystic Fibrosis Respiratory Symptom Diary‐Chronic Respiratory Infection Symptom Score; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>HR</b> : hazard ratio; <b>IL‐1β</b> : interleukin‐1β ;<b>IL‐8</b> : interleukin 8; <b>MD</b> : mean difference; <b>MPO</b> : myeloperoxidase; <b>NE</b> : neutrophil elastase; <b><i>P aeruginosa</i> </b><i>: Pseudomonas aeruginosa</i>; <b>QoL</b> : quality of life; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Dowgraded twice due to risk of bias within the trials contributing to this outcome. There was concern around randomisation and allocation concealment in 1 trial and a risk from attrition bias in the other included trial. </p> <p>b. Downgraded due to inconsistency caused by heterogeneity between the 2 studies for his outcome. </p> <p>c. Downgraded due to imprecision from low event rates.</p> <p>d. Downgraded once because there was unclear risk of bias from attrition in the 1 included trial. Although an intention‐to‐treat analysis was used, there was a 27% drop‐out rate </p> <p>e. Downgraded once due to risk of bias within the 1 included trial for this outcome. There was concern around randomisation and allocation concealment as this was not clearly stated. </p> <p>f. Downgraded once due to imprecision caused by low participant numbers and low event rates. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008037-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (12 or over) and young adults with cystic fibrosis </p> <p><b>Settings</b>: unclear if inpatient or outpatient </p> <p><b>Intervention</b>: inhaled NO (10 ppm inhaled overnight for 5 ‐ 7 days; 20 ppm or 40 ppm inhaled continuously for 44 hours) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>NO</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>mean change in FEV<sub>1</sub> % predicted from baseline </p> <p>Follow‐up: 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group is 6.17%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was<br/><b>2% lower</b> (10% lower to 6% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐1.95</b> (‐9.94 to 6.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the NO group and placebo (P = 0.63).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 48 hours to 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>In one trial 4 participants reported adverse events including epistaxis, cough and cold, increased cough and haemoptysis but all were considered mild and only possibly related to the trial treatment. In the placebo group only one adverse event was reported, which was epistaxis (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> <p>Sagel reported no serious adverse events in either NO or placebo group at either the low dose or high dose of NO (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> <p>Follow‐up: 48 hours to 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial showed a significant reduction in <i>S aureus</i> colony counts in the high‐dose NO group relative to placebo (P = 0.03) and a near significant reduction in <i>P aeruginosa</i> colony counts in the high‐dose group relative to placebo (P = 0.06) (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <p>The second trial found a significant reduction in <i>P aeruginosa</i> biofilm aggregates compared with those receiving placebo with antibiotics over the 7‐day treatment period (P = 0.029) and there was less <i>P aeruginosa</i> biofilm in the NO group compared with placebo (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>NO</b>: nitric oxide; <i><b>P aeruginosa</b>: Pseudomonas aeruginosa</i>; <b>RR</b>: risk ratio; <i><b>S aureus</b>: Staphylococcus aureus</i>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once from risk of bias because of uncertainty around selective reporting of outcomes.<br/><sup>b</sup> Downgraded once due to imprecision from very low number of participants and low event rates.<br/><sup>c</sup> Downgraded twice for risk of bias within the included trials. There were concerns around randomisation, allocation concealment, selective reporting and attrition bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008037-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: zinc supplementation (30 mg orally once daily) </p> <p><b>Comparison</b>: placebo (orally once daily) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Zinc supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> number of participants requiring IV antibiotics </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b><br/>(137 to 1000). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.85</b> (0.65 to 5.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results favour placebo, but not significantly (P = 0.25) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>mean FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial showed no difference between groups, MD ‐5.46 (95% CI ‐19.44 to 8.52) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> <p>A further paper reported that the median (IQR) FEV<sub>1</sub> % predicted value was 8.97% (‐18.23% to 0.33%) lower than baseline in the zinc group and 9.55% (‐9.59% to 12.88%) higher in the placebo group (P = 0.08) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results have been reported narratively as the outcome was reported differently in the 2 trials. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> number of participants hospitalised during the trial </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> (161 to 939). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (0.51 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All of the serious adverse events were related to exacerbations. Although no data were reported, the Abdulhamid trial reported there were no adverse events (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>number of days on IV or oral antibiotics</p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Abdulhamid reported that significantly fewer oral antibiotics alone were needed by participants in the zinc group, MD ‐17.74 (95% CI ‐26.98 to ‐8.50); but there was no significant difference between groups in the need for IV antibiotics alone, MD 0.52 (95% CI ‐3.07 to 4.11) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> <p>The Sharma trial found no significant difference in the number of days on IV or oral antibiotics (P = 0.76) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>IQR</b> : interquartile range; <b>RR</b> : risk ratio; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision caused by low event rates and a small participant numbers (n = 37).<br/><sup>b</sup> Downgraded once due to risk of bias within 1 of the included trials; there were concerns across 5 out of the 6 domains for assessing risk of bias.<br/><sup>c</sup> Downgraded once due to imprecision from small number of participants.<br/><sup>d</sup> Downgraded once due to inconsistency caused by heterogeneity between the 2 trial results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008037-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008037-sec-0009"></div> <section id="CD008037-sec-0010"> <h3 class="title" id="CD008037-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is a multi‐system disease characterised by the production of thick secretions causing recurrent pulmonary infection and pancreatic malabsorption. The altered lung environment in people with CF provides an ideal niche for bacteria such as <i>Pseudomonas aeruginosa</i> to flourish and chronic infection to develop. This results in damage to the airways leading to a decline in lung function that is largely responsible for the morbidity and mortality in CF. Over the last two decades more efficient treatment of pulmonary infections has contributed to a large increase in life‐expectancy (<a href="./references#CD008037-bbs2-0044" title="DodgeJA , LewisPA , StantonM , WilsherJ . Cystic fibrosis mortality and survival in the UK: 1947–2003. European Respiratory Journal2007;29(3):522-6. [DOI: 10.1183/09031936.00099506]">Dodge 2007</a>). The mean life expectancy for a baby born in 2003 was 42 years for a boy and 36 years for a girl (<a href="./references#CD008037-bbs2-0044" title="DodgeJA , LewisPA , StantonM , WilsherJ . Cystic fibrosis mortality and survival in the UK: 1947–2003. European Respiratory Journal2007;29(3):522-6. [DOI: 10.1183/09031936.00099506]">Dodge 2007</a>). However, the adaptive behaviour of <i>P aeruginosa</i> enables it to rapidly evolve in response to selective pressures exerted by the host environment and the use of bactericidal antibiotics. Thus, the increased use of broad spectrum antimicrobials has resulted in a reduction in their efficacy and an increase in bacterial resistance. In addition to <i>P aeruginosa</i> , other important, antibiotic‐resistant pathogens can be found in the lungs of people with CF such as <i>Burkholderia cepacia</i> and methicillin‐resistant S<i>taphylococcus aureus</i> (MRSA). </p> </section> <section id="CD008037-sec-0011"> <h3 class="title" id="CD008037-sec-0011">Description of the intervention</h3> <p>Novel agents are urgently needed, which act differently to antibiotics and can eradicate the organism without selecting for resistance and whilst re‐sensitising them to readily available antibiotics. Antibiotics commonly act by killing the organism or stopping its growth. Antibiotic adjuvants may exert their effect on the organism without killing it. Antibiotic adjuvant therapies are a diverse group of novel agents that are similar in that they act by interfering with a mechanism the organism uses to decrease its susceptibility to antibiotics; by reducing the organism's virulence; or by rendering the organism more susceptible to the host immune system. Such agents include: quorum sensing inhibitors (see below); agents that interfere with biofilm construction (the sugars fucose and galactose, and novel dendrimers acting on lectin blockade); efflux pump inhibitors that stop bacteria removing antibiotics from within the bacterial cell; glutamine as an amino acid supplement; and biological agents (such as bacteriophages) that infect bacteria causing their break‐down and demise. In the case of bacteriophages that may cause the death of the organism, they act by 'infecting' the bacteria and therefore act differently to, but alongside, conventional antibiotics. </p> <p>Some of the agents that may be considered in the review are available direct to the consumer (e.g. garlic, zinc). It is therefore conceivable that the results of the trial may alter an individual's behaviour directly. </p> </section> <section id="CD008037-sec-0012"> <h3 class="title" id="CD008037-sec-0012">How the intervention might work</h3> <p>Antibiotic adjuvants are varied in their design. Many of the bacteria causing infections in CF communicate via quorum sensing, such that the bacteria only produce virulence factors when the population of bacteria has reached a critical size. The organism can therefore remain invisible to the host immune system until the population is in a position to withstand such host attack. Some antibiotic adjuvant therapies interfere with this bacterial communication, thus potentiating the efficacy of conventional antibiotics (<a href="./references#CD008037-bbs2-0060" title="vonBodmanSB , WilleyJM , DiggleSP . Cell-cell communication in bacteria: united we stand. Journal of Bacteriology2008;190(13):4377-91. [DOI: 10.1128/JB.00486-08]">von Bodman 2008</a>). Some approaches attach to the genetic material of the organism, preventing the bacteria from becoming more resistant to antibiotics and some therapies target other mechanisms exploited by bacteria, such as the ability to form biofilms. Other antibiotic adjuvant therapies include bacteriophages or their products, viruses that directly target the bacterial cell, invade it and kill it (<a href="./references#CD008037-bbs2-0043" title="BorysowskiJ , Weber-DbrowskaB , GórskiA . Bacteriophage endolysins as a novel class of antibacterial agents. Experimental Biology and Medicine2006;231(4):366-77. [PMID: 16565432]">Borysowski 2006</a>). </p> </section> <section id="CD008037-sec-0013"> <h3 class="title" id="CD008037-sec-0013">Why it is important to do this review</h3> <p>Worldwide, there is a burgeoning interest in agents that may potentiate, refine or replace the action of antibiotics without exerting selective pressure for antibiotic resistance. It is suggested that many of these agents are less susceptible to becoming inactive (due to the organism developing resistance toward them) because in many cases they do not <i>directly</i> influence the organisms' ability to reproduce. Currently both chronic pulmonary infections and acute infective exacerbations are difficult to treat and eradication of infection may be only temporary (<a href="./references#CD008037-bbs2-0050" title="Langton-HewerSC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD004197. [DOI: 10.1002/14651858.CD004197.pub4]">Langton‐Hewer 2017</a>; <a href="./references#CD008037-bbs2-0052" title="LoDKH , MuhlebachMS , SmythAR . Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database of Systematic Reviews2018, Issue 7. Art. No: CD009650. [DOI: 10.1002/14651858.CD009650.pub4]">Lo 2018</a>; <a href="./references#CD008037-bbs2-0054" title="ReganKH , BhattJ . Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database of Systematic Reviews2019, Issue 4. Art. No: CD009876. [DOI: 10.1002/14651858.CD009876.pub4]">Regan 2019</a>). With research proceeding along diverse paths and individuals making decisions regarding supplementing conventional treatment with high‐street products, there is a need to evaluate current evidence to advise people with CF and their clinicians and to direct research targets. </p> <p>This is an update of previous reviews (<a href="./references#CD008037-bbs2-0061" title="HurleyMN , ForresterDL , SmythAR . Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD008037. [DOI: 10.1002/14651858.CD008037.pub2]">Hurley 2010</a>; <a href="./references#CD008037-bbs2-0062" title="HurleyMN , ForresterDL , SmythAR . Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008037. [DOI: 10.1002/14651858.CD008037.pub3]">Hurley 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008037-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008037-sec-0014"></div> <p>To determine if antibiotic adjuvant therapies improve clinical and microbiological outcome of pulmonary infection in people with CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008037-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008037-sec-0015"></div> <section id="CD008037-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008037-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD008037-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults and children with CF, diagnosed using the Cystic Fibrosis Foundation consensus statement (<a href="./references#CD008037-bbs2-0057" title="RosensteinBJ , Cutting GP for the Cystic Fibrosis Foundation consensus panel. The diagnosis of cystic fibrosis: A consensus statement. Journal of Pediatrics1998;132(4):589-95. [DOI: 10.1016/S0022-3476(98)70344-0 ]">Rosenstein 1998</a>). Therefore, a diagnosis of CF should be based on: </p> <p> <ul id="CD008037-list-0001"> <li> <p>presence of one or more characteristic phenotypic features;</p> </li> <li> <p>or a positive newborn screening test result;</p> </li> <li> <p>or a history of CF in a sibling and laboratory evidence of an abnormality in the cystic fibrosis transmembrane regulator (CFTR) as documented by an elevated sweat chloride concentration or the identification of mutations in each CFTR gene known to cause CF or in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium. </p> </li> </ul> </p> <p>As no standardised, validated definitions of acute exacerbation or chronic infection exists, we have employed the definitions employed by the CF Trust Antibiotic Working Group (<a href="./references#CD008037-bbs2-0059" title="UK Cystic FIbrosis Antibiotic Working Group. Antibiotic Treatment for Cystic Fibrosis - 3rd Edition. Cystic Fibrosis Trust2009.">UK Cystic Fibrosis Trust Antibiotic Working Group</a>) alongside those identified by Rosenfeld (<a href="./references#CD008037-bbs2-0056" title="RosenfeldM , EmersonJ , Williams-WarrenJ , PepeM , SmithA , MontgomeryB , et al. Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics2001;139(3):359-65. [DOI: 10.1067/mpd.2001.117288]">Rosenfeld 2001</a>). An acute exacerbation will be defined as at least four of the following (<a href="./references#CD008037-bbs2-0059" title="UK Cystic FIbrosis Antibiotic Working Group. Antibiotic Treatment for Cystic Fibrosis - 3rd Edition. Cystic Fibrosis Trust2009.">UK Cystic Fibrosis Trust Antibiotic Working Group</a>): </p> <p> <ul id="CD008037-list-0002"> <li> <p>increased productive cough or breathlessness;</p> </li> <li> <p>changes in the appearance or volume of sputum;</p> </li> <li> <p>new signs on auscultation;</p> </li> <li> <p>new chest radiograph signs;</p> </li> <li> <p>loss of appetite;</p> </li> <li> <p>fall in respiratory function;</p> </li> <li> <p>fever requiring treatment with intravenous antibiotics.</p> </li> </ul> </p> <p>Alternatively, an acute exacerbation was defined by the following score meeting or exceeding 2.6 (<a href="./references#CD008037-bbs2-0056" title="RosenfeldM , EmersonJ , Williams-WarrenJ , PepeM , SmithA , MontgomeryB , et al. Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics2001;139(3):359-65. [DOI: 10.1067/mpd.2001.117288]">Rosenfeld 2001</a>). </p> <p> <div class="table" id="CD008037-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Feature</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Score</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased exercise tolerance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased sputum or cough congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>School or work absenteeism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased adventitial sounds on lung examination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> </tr> </tbody> </table> </div> </p> <p>The bacterium targeted by such an approach will not be limited by species. A chronic <i>P aeruginosa</i> infection will be defined by more than 50% of months in a year when samples had been taken being <i>P aeruginosa</i> culture‐positive (<a href="./references#CD008037-bbs2-0051" title="LeeTW , BrownleeKG , DentonM , LittlewoodJ , ConwaySP . Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatric Pulmonology2004;37(2):104-10. [DOI: 10.1002/ppul.10401]">Lee 2004</a>). We previously had used the UK Cystic Fibrosis Trust definition of two or more occasions of <i>P aeruginosa</i> isolation over six months (<a href="./references#CD008037-bbs2-0058" title="UK Cystic Fibrosis Trust Infection Control Group. Pseudomonas aeruginosa infection in people with cystic fibrosis: Suggestions for prevention and infection control. Report of the UK Cystic Fibrosis Infection Control Group2004. [ISBN: 0-9540536-9-9]">UK Cystic Fibrosis Trust 2004</a>); however, the definition cited above more closely replicates current clinical practice. A similar approach will be used for other infections, except for non‐tuberculous mycobacteria which will be considered chronic is infection persists despite a year of intensive eradication treatment. </p> <p>In the case of trials including both clinical scenarios or less defined criteria, we shall aim to manage these separately using a pragmatic approach. </p> </section> <section id="CD008037-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Antibiotic adjuvant agents compared to conventional antibiotics (either alone or in combination), placebo or no therapy via any route of administration. </p> <p>Antibiotic adjuvant agents are those which augment the host immune response or potentiate antibiotic action. The adjuvants themselves may exert a direct killing or bacteriostatic effect on the organism but their primary role is to augment the effect of the co‐administered antibiotics. Such adjuvants include those that exert an effect on bacterial susceptibility to antibiotics and include efflux pump inhibitors (agents that block the action of efflux pumps ‐ pumps on the cell membrane that remove toxic substances from within the bacterium) or quorum sensing inhibitors. Other adjuvants change the physical resistance of an infection (e.g. lectin inhibitors) or those that act at the genetic level of the organism to prevent the acquisition of antibiotic resistance (e.g. anti‐sense strategies). </p> <p>Biological agents (such as bacteriophages) were eligible for inclusion in this review. Agents were considered which are intended to treat bacteria, fungi and viruses.  </p> <p>We excluded trials of agents that physically alter the host environment (e.g. gene therapy, immunotherapy); anti‐inflammatory agents (e.g. steroids, ibuprofen); agents that alter mucociliary clearance (e.g. mannitol, hypertonic saline and dornase alfa); physical interventions (such as physiotherapy and exercise); and environmental changes (such as an infection control policy).  </p> </section> <section id="CD008037-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008037-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008037-list-0003"> <li> <p>Pulmonary exacerbations (protocol defined)</p> </li> <li> <p>Respiratory function</p> <ol id="CD008037-list-0004"> <li> <p>per cent (%) predicted forced expiratory volume in one second (FEV<sub>1</sub>) values for age, sex and height </p> </li> <li> <p>% predicted forced vital capacity (FVC) values for age, sex and height</p> </li> <li> <p>other validated measures of respiratory function</p> </li> </ol> </li> <li> <p>Adverse events (AEs)</p> <ol id="CD008037-list-0005"> <li> <p>mild (not requiring treatment)</p> </li> <li> <p>moderate (requiring treatment or admission)</p> </li> <li> <p>severe (life‐threatening)</p> </li> </ol> </li> </ol> </p> </section> <section id="CD008037-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008037-list-0006"> <li> <p>Need for antibiotics (oral, inhaled or intravenous (IV))</p> <ol id="CD008037-list-0007"> <li> <p>Time to next course of antibiotics (oral or IV)</p> </li> <li> <p>Antibiotic consumption (days of antibiotic use)</p> </li> </ol> </li> <li> <p>Quality of life (QoL) using standardised and validated QoL scores (e.g. CFQ‐R (<a href="./references#CD008037-bbs2-0053" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) and symptom scores (e.g. Respiratory and Systemic Symptoms Questionnaire (RSSQ), Respiratory Symptom Score (RSS) (<a href="./references#CD008037-bbs2-0046" title="GossCH , BurnsJL . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax2007;62(4):360-7. [PMID: 17387214]">Goss 2007</a>)) </p> <ol id="CD008037-list-0008"> <li> <p>time of work or school</p> </li> <li> <p>treatment burden (e.g. challenges of living with CF evaluation)</p> </li> </ol> </li> <li> <p>Change in sputum microbiology:</p> <ol id="CD008037-list-0009"> <li> <p>emergence of new CF pathogens, including development of allergic bronchopulmonary aspergillosis (ABPA) (increase in serum IgE with clinical or radiological features) </p> </li> <li> <p>quantitative microbiology (change in numbers of pathogens isolated from respiratory tract secretion culture) </p> </li> </ol> </li> <li> <p>Change in inflammatory markers</p> <ol id="CD008037-list-0010"> <li> <p>serum (C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR))</p> </li> <li> <p>sputum (IL‐8, leukotrienes, cytokines)</p> </li> </ol> </li> <li> <p>Mortality</p> </li> </ol> </p> <p>We assessed these outcomes for both chronic infection and acute infective exacerbations where data allowed. We assessed and analysed results separately for the two clinical scenarios at the time‐points detailed below (<a href="#CD008037-sec-0028">Data extraction and management</a>). </p> </section> </section> </section> <section id="CD008037-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There are no restrictions regarding language or publication status.</p> <section id="CD008037-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched for relevant trials from the Group's Cystic Fibrosis Trials Register using the terms 'pulmonary infection' AND 'non‐antibiotic'.<br/><br/>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the <i>Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective hand‐searching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of last search of the Cystic Fibrosis Trials Register: 16 January 2020.</p> <p>We also searched MEDLINE separately; the search strategy is given in the appendices (<a href="./appendices#CD008037-sec-0114">Appendix 1</a>; <a href="./appendices#CD008037-sec-0115">Appendix 2</a>). </p> <p>Date of last search of MEDLINE: 14 February 2019.</p> <p>We also searched the ongoing trials registries as detailed in the appendices (<a href="./appendices#CD008037-sec-0116">Appendix 3</a>); date of last search: 06 April 2020 </p> </section> <section id="CD008037-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We hand‐searched reference lists of identified trials. We also contacted primary authors of identified trials and research institutions or biotech companies for unpublished trials for the original review. We have contacted authors for clarification and extra data for this update. </p> </section> </section> <section id="CD008037-sec-0026"> <h3 class="title" id="CD008037-sec-0026">Data collection and analysis</h3> <p>We used methods described in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD008037-bbs2-0048" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We aimed to analyse acute infective exacerbations and chronic infection separately as defined previously in the section <a href="#CD008037-sec-0018">Types of participants</a>. There were no interventions with outcomes in both acute and chronic conditions. We would aim to make this comparison in future updates of this review if there are suitable new trials. </p> <section id="CD008037-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Originally two authors (MH and DF) independently reviewed all potential trials for inclusion in the original review. For the 2020 update MH and SS reviewed the potential trials. These two authors examined the title and abstract of potential publications to remove those that did not meet inclusion criteria (e.g. single case reports, reviews etc.). We then examined the full text publications of the remaining trials to determine if they met the eligibility criteria. In the case that we were unable to reach agreement regarding the determination of eligibility by discussion, we would have sought the opinion of the third independent author (AS); however, there were no such occurrences. Authors examined publications potentially eligible for inclusion for duplication by comparing author, institution, trial detail (intervention, dosing, timing etc.) and participant demographics. </p> </section> <section id="CD008037-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the 2020 update, two authors (MH and SS) independently extracted information from the eligible trials using a data collection form. We discussed the results from each data extraction form to ensure agreement of interpretation; if there had been an absence of agreement, we planned to seek the opinion from a third author (AS). </p> <p>It is possible that during a trial a participant may experience more than one exacerbation; in this event the shortest time between exacerbations would have been used. </p> <p>Where trials, particularly with regard to chronic infection, take multiple assessments of individuals over a protracted time period, we would have defined time‐frames of follow‐up to represent short‐, medium‐ and long‐term follow‐up. For the acute exacerbation trials we would have assessed data at time points of up to two weeks (standard duration of exacerbation therapy), over two weeks and up to six weeks (to assess efficacy of sustaining an effect). As previously discussed we would have assessed the outcome measure, time to next exacerbation as an indicator of long‐term effectiveness of antibiotic therapy. For the chronic infection trials, we would have taken assessment time points at one month, over one month and up to three months, over three months and up to six months, over six months and up to 12 months and annually thereafter. For future updates, if outcome data are recorded at other time points, we shall consider examining these as well. </p> </section> <section id="CD008037-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The authors assessed the risk of bias using the 'Risk of bias' assessment tool as documented in section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008037-bbs2-0048" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). In particular, authors considered generation of allocation sequence and allocation concealment, blinding and incomplete outcome data. We also sought to identify selective outcome reporting by comparing those outcomes reported in the published paper to those considered in the protocol. For the 2020 update, MH and SS assessed the risk of bias for any new trials identified. We did not reassess the risk of bias for those trials already included in the review. </p> </section> <section id="CD008037-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>In identifying any treatment effect, we had planned to analyse the results of intervention measures separately for acute exacerbation and chronic infection. For dichotomous data we planned to analyse these by calculating the relative risk (RR) and its 95% confidence intervals (CIs) on an intention‐to‐treat basis (ITT). No trials reported mortality as an outcome measure, although we had planned to combine data in order to calculate the hazard ratio (HR) with 95% CIs, or if it is more appropriate, to describe the outcomes of mortality and adverse events descriptively. </p> <p>For continuous outcome variables, we documented the mean difference (MD) of effect and standard deviation (SD) of each variable. We did not use a standardised scoring system; if trials had documented scores using the same scoring system, we had planned to calculate the MD and 95% CIs. If trials had used different validated scoring systems, we would have calculated the standardised mean difference (SMD) and 95% CIs. </p> <p>No trial reported data for 'time to next exacerbation'. If in future updates, such data become available, we plan to calculate the HR and its 95% CIs (appropriate as the risk of an exacerbation is not dependent upon other variables and should be uniform throughout the time period). </p> <p>We describe count data narratively.</p> </section> <section id="CD008037-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Cross‐over trials are difficult to include as in many cases the duration of action of individual treatments may be prolonged. As a result we planned to only consider the first treatment phase of a cross‐over trial and would not include such trials in full until such time that duration of action detail is understood, a washout period provided, measures of treatment effect are available and the data are available from each treatment phase. When considering trials of long duration (and measures of number of exacerbations or requirement of antibiotics) repeated values should be available for each participant. </p> </section> <section id="CD008037-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In the case where it was obvious that any of the included publications missed important data from the review's primary or secondary outcomes, the authors approached the primary investigator for clarification or more detail. This was the case for the trial by Abdulhamid, who kindly provided the additional data (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). If, in future, we do not receive any reply from primary investigators to possible enquires, we shall seek to account for all missing data by contact with the co‐investigators. </p> </section> <section id="CD008037-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>If we had identified data from multiple trials of a common therapy, we would have performed a meta‐analysis of these trials. To assess heterogeneity between trials in the meta‐analysis, we planned to use the I² statistic (<a href="./references#CD008037-bbs2-0047" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We would have based our interpretation of this statistic on the guide given in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> such that we would regard an I² statistic below 40% as not important, between 30% and 60% as representing moderate heterogeneity, between 50% and 90% representing substantial and over 75% representing considerable heterogeneity (<a href="./references#CD008037-bbs2-0048" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We would have interpreted this within the context of magnitude and direction of any effect and the strength of evidence for any heterogeneity, including a CI if possible for the I² result. </p> </section> <section id="CD008037-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted the primary author of each included trial for the original iteration of the review to determine if they knew of other trials which have been completed but may not have been published. This process might have identified some small older trials and in this instance we could have determined the effects of these along with any reporting biases with the construction of funnel plots, accepting the multiple causes of asymmetry. When available, we made efforts to identify selective reporting of results by comparing the trial protocol (as published on a clinical trials register) with the final published results and by comparing the methods and results as detailed in the publication for any inconsistency in reporting. </p> </section> <section id="CD008037-sec-0035"> <h4 class="title">Data synthesis</h4> <p>In the event of multiple trials we planned to analyse data using a fixed‐effects model unless the measures of heterogeneity were at least substantial (as defined above) in which case a random‐effects model would be most appropriate (<a href="./references#CD008037-bbs2-0055" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.">RevMan 2011</a>). </p> </section> <section id="CD008037-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we had identified a sufficient number of trials, we planned to undertake the following subgroup analyses for each class of agent: </p> <p> <ol id="CD008037-list-0011"> <li> <p>adults (aged 18 years and over) versus children;</p> </li> <li> <p>presence or absence of chronic infection (defined as three or more isolates in one year) with: </p> <ol id="CD008037-list-0012"> <li> <p><i>P aeruginosa;</i> </p> </li> <li> <p><i>B cepacia;</i> </p> </li> <li> <p>MRSA.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD008037-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>In the case that we had multiple analyses, we would have determined the effect our decisions made relating to arbitrary categorisations by repeating these analyses with different categorisations; for example, repeating the analyses of treatment effect with different measures of short, medium and long term. With regard to determining the effect of small trials on the end result, we would repeat the analyses without these small trials (e.g. participant numbers less than 20 in each group) to determine their effect. </p> </section> <section id="CD008037-sec-0038"> <h4 class="title">Summary of findings tables</h4> <p>We have presented a summary of findings table for each separate comparison in the review: </p> <p> <ul id="CD008037-list-0013"> <li> <p>β‐carotene versus placebo;</p> </li> <li> <p>garlic versus placebo;</p> </li> <li> <p>monoclonal antibody KB001‐A versus placebo;</p> </li> <li> <p>inhaled nitric oxide versus placebo;</p> </li> <li> <p>zinc versus placebo.</p> </li> </ul> </p> <p>Within each table we present the following outcomes which we selected based on their clinical relevance and importance to the CF community: </p> <p> <ul id="CD008037-list-0014"> <li> <p>pulmonary exacerbations;</p> </li> <li> <p>respiratory function;</p> </li> <li> <p>adverse events</p> </li> <li> <p>need for antibiotics;</p> </li> <li> <p>QoL;</p> </li> <li> <p>sputum microbiology; and</p> </li> <li> <p>inflammatory markers.</p> </li> </ul> </p> <p>We determined the quality of the evidence using the GRADE approach and starting from a judgement of high quality, downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if we considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008037-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008037-sec-0039"></div> <section id="CD008037-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008037-sec-0041"> <h4 class="title">Results of the search</h4> <p>We have presented the results of the searches in a PRISMA chart (<a href="#CD008037-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008037-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008037-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The search strategy identified a total of 42 trials. Of these trials, eight investigating the use of antibiotic adjuvant therapies for chronic infection are included in the review (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>) and 27 trials were excluded. Two trials are still ongoing and will be assessed for inclusion in the review when they are completed and results available (<a href="./references#CD008037-bbs2-0042" title="DaviesJ . Oligo G: a novel mucolytic from basic science to clinical trials. Pediatric Pulmonology2017;52 Suppl 47:150-1. [CFGD REGISTER: BD235c] DonaldsonSH , BennettWD , ZemanK , PresslerT , GowL , ConwayJ , et al. A first in class mucus conditioning drug-effect of an inhaled alginate oligosaccharide (oligo-g) on mucus clearance in subjects with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:305. [CFGD REGISTER: BD235d] PresslerT , DonaldsonS , SmerudKT , MyrsetAH , OligoG Study Team. A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 1:S1. [CFDG REGISTER: BD235b] PresslerT , DonaldsonSH , DaviesJC , Hilde MyrsetA . A double-blind, randomised, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) administered for 28 days in subjects with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl:271. [CFGD REGISTER: BD235a] PresslerT . A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984). Clinicaltrials.gov August 2016. ">Pressler 2017</a>; Zabner 2009a). Five trials are currently awaiting classification (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>; <a href="./references#CD008037-bbs2-0037" title="BoskabadyM , Nemat KhorasaniE , MansouriF , SoltanianE , BoskabadyM . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Journal of Research in Medical Sciences2012;17(12):jrms.mui.ac.ir/index.php/jrms/article/view/8833. KhorasaniEN , MansouriF . Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. In: Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria. 2009:722s. [ABSTRACT NO.: P4032] [CENTRAL: 793188] [CFGD REGISTER: GN255] ">Khorasani 2009</a>; <a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a><a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>; <a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>). Two are cross‐over trials and we are awaiting first‐arm data (<a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>; <a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>); it is unclear at this stage whether one of the trials is randomised as it is only presented as an abstract (<a href="./references#CD008037-bbs2-0037" title="BoskabadyM , Nemat KhorasaniE , MansouriF , SoltanianE , BoskabadyM . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Journal of Research in Medical Sciences2012;17(12):jrms.mui.ac.ir/index.php/jrms/article/view/8833. KhorasaniEN , MansouriF . Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. In: Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria. 2009:722s. [ABSTRACT NO.: P4032] [CENTRAL: 793188] [CFGD REGISTER: GN255] ">Khorasani 2009</a>). The remaining two trials are only presented as conference abstracts (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>; <a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a>). </p> </section> <section id="CD008037-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD008037-sec-0043"> <h5 class="title">Acute respiratory exacerbations</h5> <p>None of the included trials involved the treatment of acute infectious exacerbations.</p> </section> <section id="CD008037-sec-0044"> <h5 class="title">Chronic infection</h5> <p>Eight trials with a total of 350 participants with chronic infection are included.</p> <section id="CD008037-sec-0045"> <h6 class="title">Trial design</h6> <p>All eight trials were randomised, double‐blind, placebo‐controlled trials of parallel design. Two of the trials were three‐armed trials, one comparing two different doses of KB001‐A to placebo (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>) and the other comparing high‐ and low‐dose nitric oxide (NO) with placebo (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). Two of the trials were multicentre and both were carried out in the USA (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The remaining six trials were single centre; two were carried out in the USA (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>), two in the UK (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>), one in Austria (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>) and one in Northern India (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). The duration of the trials ranged from a 48‐hour single‐dose trial (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>) to one year (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </section> <section id="CD008037-sec-0046"> <h6 class="title">Participants</h6> <p>The number of participants in the included trials ranged from 12 (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>) to 169 (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). Six of the trials included both adults and children (age range 6.8 to 54 years) (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>) and the remaining two trials recruited children only (age range 5 to 18 years) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). Most of the trials required a confirmed diagnosis of CF for inclusion, but two of the trials did not make this explicit (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> </section> <section id="CD008037-sec-0047"> <h6 class="title">Interventions</h6> <p>All eight trials compared the intervention to a placebo.</p> <p>One trial (n = 24) reported on a high‐dose of β‐carotene supplementation at 1 mg/kg/day for three months followed by low‐dose regimen of 10 mg/day for three months (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). One trial (n = 34) compared a garlic capsule once daily (656 mg of garlic oil macerate and 10 mg cardamom oil) to placebo (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). Two trials (n = 196) reported on a monoclonal antibody preparation KB001‐A, but at different doses and for different durations (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Jain (n = 169) looked at the effect of up to five IV infusions of 10 mg/kg of KB001‐A once every four weeks during the 16‐week treatment period (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>), whilst Milla (n = 27) looked at the effect of a single IV infusion of either 3 mg/kg or 10 mg/kg given over one hour (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Two trials (n = 30) assessed inhaled NO, but again at different doses and duration (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). The Howlin trial (n = 12) administered 10 ppm NO delivered via nasal cannula for eight hours overnight for five to seven days of therapy (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). The second trial (n = 18) of inhaled NO studied a 'low' dose of 20 ppm via nasal cannula for 44 hours in one arm and a 'high' dose of 40 ppm via nasal cannula for 44 hours (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). The remaining two trials (n = 66) reported on zinc supplementation at a dose of 30 mg per day, both for a duration of 12 months (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <p>The dose regimens for each supplement are detailed in the tables (<a href="./references#CD008037-sec-0127" title="">Characteristics of included studies</a>). </p> </section> <section id="CD008037-sec-0048"> <h6 class="title">Outcomes</h6> <p>Three trials reported our primary outcome of pulmonary exacerbations (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). Renner looked at the number of pulmonary exacerbations over six months during supplementation with β‐carotene (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>), whilst the two 12‐month zinc trials looked at respiratory tract infections against a defined criteria (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>) or the number of pulmonary exacerbations requiring antibiotics (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <p>All eight trials reported some measure of respiratory function over different time periods; six of these specifically measured FEV<sub>1</sub> (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>), whilst Howlin and Milla also measured FVC (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>) and Milla also measured FEF<sub>25 - 75</sub> (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Both of the trials looking at the effects of NO reported adverse events (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>), as did one of the KB001‐A trials (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>) and one of the zinc trials (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <p>Four trials reported on the first of our secondary outcomes, need for antibiotics (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). Only Jain reported on the time to a need for antibiotics (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>), whilst the remaining three trials reported the number of days or courses of antibiotics needed (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). The two trials of KB001‐A measured QoL; one trial used the CFQ‐R (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>) and one trial measured the change in respiratory symptoms (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). None of the trials looked at the emergence of new pathogens, but four trials looked at changes in quantitative microbiology (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>) and three trials reported on inflammatory markers (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> </section> </section> </section> <section id="CD008037-sec-0049"> <h4 class="title">Excluded studies</h4> <p>Publications that were obviously not relevant to the review after interrogation of the abstracts were excluded and are not listed in the review; we have listed a total of 27 trials as excluded. </p> <p>Nine trials were excluded for methodological reasons: seven trials were not RCTs or quasi‐RCTs (<a href="./references#CD008037-bbs2-0012" title="DurairajL , LaunspachJ , WattJL , MohamadZ , KlineJ , ZabnerJ . Safety assessment of inhaled xylitol in subjects with cystic fibrosis. Journal of Cystic Fibrosis 2007 Jan;6(1):31-4. ">Durairaj 2007</a>; <a href="./references#CD008037-bbs2-0018" title="HomnickDN , SpillersCR , CoxSR , CoxJH , YeltonLA , DeLoofMJ , et al. Single- and multiple-dose-response relationships of beta-carotene in cystic fibrosis [see comment]. Journal of Pediatrics1995;127(3):491-4. [CFGD REGISTER: GN68] ">Homnick 1995</a>; <a href="./references#CD008037-bbs2-0019" title="KollbergH , CarlanderD , OlesenH , WejakerPE , JohannessonM , LarssonA . Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatric Pulmonology2003;35(6):433-40. NilssonE , KollbergH , JohannessonM , WejakerPE , CarlanderD , LarssonA . More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. Journal of Medicinal Food2007;10(2):375-8. NilssonE , LarssonA , OlesenHV , WejakerPE , KollbergH . Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatric Pulmonology2008;43(9):892-9. ">Kollberg 2003</a>; <a href="./references#CD008037-bbs2-0022" title="LandsLC , IskandarM , BeaudoinN , MeehanB , DauletbaevN , BerthiuameY . Dietary supplementation with pressurized whey in patients with cystic fibrosis. Journal of Medicinal Food2010;13(1):77-82. [DOI: 10.1089/jmf.2008.0326]">Lands 2010</a>; <a href="./references#CD008037-bbs2-0031" title="SagelSD , SontagMK , AnthonyMM , EmmettP , PapsKA . Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. Journal of Cystic Fibrosis2011;10(1):31-6. [DOI: 10.1016/j.jcf.2010.09.005]">Sagel 2011</a>; <a href="./references#CD008037-bbs2-0034" title="Winklhofer-RoobBM , PuhlH , KhoschsorurG , van't HofMA , EsterbauerH , ShmerlingDH . Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. Free Radical Biology &amp; Medicine1995;18(5):849-59. Winklhofer-RoobBM , Schlegel-HaueterSE , KhoschsorurG , van't HofMA , SuterS , ShmerlingDH . Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation. Pediatric Research1996;40(1):130-4. Winklhofer-RoobBM , van't HofMA , ShmerlingDH . Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study.[erratum appears in Acta Paediatr 1996 Jan;85(1):124]. Acta Paediatrica 1995 Oct;84(10):1132-6. ">Winklhofer‐Roob 1995</a>); one was a single case report (<a href="./references#CD008037-bbs2-0021" title="KutateladzeM , AdamiaR . Phage therapy experience at the Eliava Institute. Medecine et Maladies Infectieuses2008;38(8):426-30. ">Kutateladze 2008</a>); and two were cross‐over trials which had no data from the first phase of the trial available for analysis; one assessed edetate sodium (EDTA) aerosolisation (<a href="./references#CD008037-bbs2-0010" title="BrownJ , MellisCM , WoodRE . EDTA aerosol in pseudomonal lung infection. In: 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:4.10. [CFGD REGISTER: PI235a] BrownJ , MellisCM , WoodRE . Edetate sodium aerosol in Pseudomonas lung infection in cystic fibrosis. American Journal of Diseases of Children1985;139(8):836-9. [CFGD REGISTER: PI235b] ">Brown 1985</a>) and one zinc supplementation (<a href="./references#CD008037-bbs2-0030" title="Safai-KuttiS , SelinE , LarssonS , JagenburgR , StenG , KjellmerI . Zinc therapy in children with cystic fibrosis. Beitraege zur Infusionstherapie1991;27:104-14. [CFGD REGISTER: GN36] ">Safai‐Kutti 1991</a>). </p> <p>A further 16 trials were excluded as the interventions were not considered to be antibiotic adjuvant therapies. We excluded one trial investigating the effect of polyunsaturated fats (<a href="./references#CD008037-bbs2-0029" title="PanchaudA , SautyA , KernenY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clinical Nutrition2006;25(3):418-27. [CFGD REGISTER: GN109b] [DOI: 10.1016/j.clnu.2005.10.011]PanchaudA , SautyA , KernenY , DecosterdLA , BuclinT , RouleM . Dietary supplementation with omega-3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Suppl:S88. [CFGD REGISTER: GN109a] ">Panchaud 2006</a>) and another trial of fatty acid supplements (<a href="./references#CD008037-bbs2-0028" title="OlveiraG , OlveiraC , AcostaE , EspíldoraF , Garrido-SánchezL , García-EscobarE . Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Archivos de Bronconeumologia2010;46(2):70-7. ">Olveira 2010</a>); these interventions appear to exert an independent anti‐inflammatory effect and so were considered not to meet our definition of an antibiotic adjuvant (as described in our exclusion criteria). A phase 2 trial of a CXCR2 antagonist was excluded as the mechanism of action is anti‐inflammatory (<a href="./references#CD008037-bbs2-0025" title='MossRB , MistrySJ , KonstanMW , PilewskiJM , KeremE , Tal-SingerR , et al. Online Supplement to: "Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis". Journal of Cystic Fibrosis2013;13(3):241-8. [CENTRAL: 1000130] [CFGD REGISTER: PI275b] [NCT00903201]MossRB , MistrySJ , KonstanMW , PilewskiJM , KeremE , Tal-SingerR , et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. Journal of Cystic Fibrosis2013;12(3):241-8. [CENTRAL: 967627] [CFGD REGISTER: PI275a] [JID: 101128966] [PMID: 22995323] [SI: ClinicalTrials.gov/NCT00903201]'>Moss 2013</a>). One trial of magnesium (<a href="./references#CD008037-bbs2-0014" title="Gontijo-AmaralC , GuimarãesEV , CamargosP . Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial. American Journal of Clinical Nutrition2012;96(1):50-6. [CENTRAL: 880141] [CFGD REGISTER: GN241] [DOI: 10.3945/ajcn.112.034207] [PMID: 22648717]">Gontijo‐Amaral 2012</a>) and another of L‐arginine (<a href="./references#CD008037-bbs2-0015" title="GrasemannH , TullisE , RatjenF . A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis. Pediatric Pulmonology2011;46 Suppl 34:293. [ABSTRACT NO.: 229] [CENTRAL: 921615] [CFGD REGISTER: GN233a] [DOI: 10.1016/j.jcf.2012.12.008]GrasemannH , TullisE , RatjenF . Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO.: 81] [CENTRAL: 871494] [CFGD REGISTER: GN233b] ">Grasemann 2013</a>) were excluded as an adjuvant effect does not appear to have been demonstrated in either trial. Two trials of immunotherapy agents for chronic infection were also excluded (<a href="./references#CD008037-bbs2-0020" title="KollbergH , LarssonA , NilssonE . Anti-pseudomonas IGY ready for phase III. Pediatric Pulmonology2010;45(Suppl 33):343. [ABSTRACT NO.: 345] [CFGD REGISTER: PI252a] LarssonA . Phase III study (IMPACTT) on anti-pseudomonas IgY. Journal of Cystic Fibrosis2011;10(Suppl 1):S24. [ABSTRACT NO.: 92] [CFGD REGISTER: PI252b] SchusterA , BendJ , HoibyN , VerdePE , RottmannA , LarssonA , et al. Clinical study to evaluate an anti-Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011-000801-39). Journal of Cystic Fibrosis2019;18:S23. [ABSTRACT NO.: WS12-5] [CENTRAL: CN-01990653] [CFGD REGISTER: PI252d] [EMBASE: 2001976053]">Kollberg 2010</a>; <a href="./references#CD008037-bbs2-0027" title="NCT01455675. Phase III study to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients. clinicaltrials.gov/ct2/show/NCT01455675 (first received 20 October 2011). ">NCT01455675</a>). Two trials of miglustat were excluded as this agent acts at the host genetic level and is not an adjuvant (<a href="./references#CD008037-bbs2-0026" title="NCT00742092. Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fibrosis homozygous for the F508del mutation. clinicaltrials.gov/ct2/show/NCT00742092 (first received 27 August 2008). ">NCT00742092</a>; <a href="./references#CD008037-bbs2-0023" title="LeonardA , DingemanseJ , LebecqueP , LealT . Oral miglustat in homozygous F508del CF patients. Journal of Cystic Fibrosis2010;9 Suppl 1:S20. [ABSTRACT NO.: 75] [CFGD REGISTER: BD193a] LeonardA , LebecqueP , DingemanseJ , LealT . A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. Journal of Cystic Fibrosis2012;11(3):231-6. [CFGD REGISTER: BD193b] [DOI: 10.1016/j.jcf.2011.12.004]">Leonard 2012</a>). Two trials examined the effect of vitamin D supplementation, but not as an antibiotic adjuvant (<a href="./references#CD008037-bbs2-0009" title='AlvarezJA , ChongEY , WalkerDI , ChandlerJD , MichalskiES , GrossmannRE , et al. Corrigendum to "Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: a pilot randomized study of high-dose vitamin D3 administration". Metabolism: Clinical and Experimental2017;74:41-2. [CFGD REGISTER: GN217h] AlvarezJA , ChongEY , WalkerDI , ChandlerJD , MichalskiES , GrossmannRE , et al. Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: a pilot randomized study of high-dose vitamin D3 administration. Metabolism: Clinical and Experimental2017;70:31-41. [CFGD REGISTER: GN217f] AlvarezJA , SmithEM , JonesDP , GrossmanRE , FredianiJK , UppalK , et al. Discovery-based, high resolution plasma metabolomics following a vitamin D3 intervention in adult patients with cystic fibrosis. Pediatric Pulmonology2014;49 Suppl 38:418-9. [ABSTRACT NO.: 551] [CFGD REGISTER: GN217g] GrossmannRE , ZughaierS , KumariM , SeydafkanS , LiuS , LylesR , et al. Clinical responses to a novel vitamin D supplementation strategy in adult CF patients hospitalized for pulmonary exacerbations. Pediatric Pulmonology2011;46 Suppl 34:404. [ABSTRACT NO.: 526] [CFGD REGISTER: GN217b] GrossmannRE , ZughaierSM , KumariM , SeydafkanS , LylesRH , LiuS , et al. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: a randomized, controlled trial. Dermato-endocrinology2012;4(2):191-7. [CFGD REGISTER: GN217d] GrossmannRE , ZughaierSM , LiuS , LylesRH , TangprichaV . Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. European Journal of Clinical Nutrition2012;66(9):1072-4. [CFGD REGISTER: GN217c] GrossmannRE , ZughaierSM , LylesRH , LiuS , SueblinvongV , SchechterMS , et al. High dose vitamin D is associated with decreased inflammatory markers and increased number of hospital-free days in adults with cystic fibrosis: A pilot study. FASEB journal2012;26 Suppl:no pagination. [CFGD REGISTER: GN217e] KumariM , ColmanL , GrossmannR , WolfendenLL , TangprichaV . High dose vitamin D supplements in cystic fibrosis patients hospitalized for respiratory exacerbation. Pediatric Pulmonology2009;44 Suppl 32:409. [ABSTRACT NO.: 549] [CFGD REGISTER: GN217a] '>Alvarez 2017</a>; <a href="./references#CD008037-bbs2-0033" title="LeeMJ , AlvarezJA , SmithEM , KillileaDW , ChmielJF , JosephPM , et al. Changes in mineral micronutrient status during and after pulmonary exacerbation in adults with cystic fibrosis. Nutrition in Clinical Practice2015;30(6):838-43. [CFGD REGISTER: GN262a] LeeMJ , KearnsMD , SmithEM , HaoL , ZieglerTR , AlvarezJA , et al. Free 25-hydroxyvitamin D concentrations in cystic fibrosis. American Journal of the Medical Sciences2015;350(5):374-9. [CFGD REGISTER: GN262c] NCT01426256. Vitamin D for enhancing the immune system in cystic fibrosis. clinicaltrials.gov/show/NCT01426256 (first received 31 August 2011). [CFGD REGISTER: GN262b] TangprichaV , MichalskiE , LukemireJ , BinongoJ , JuddS , ZieglerT , et al. High-dose vitamin D3 during acute pulmonary exacerbation in cystic fibrosis: a multi-center, double-blind, placebo-controlled trial. Pediatric Pulmonology2017;52 Suppl 47:471-2. [CFGD REGISTER: GN262e] TangprichaV , SmithEM , BinongoJ , JuddSE , ZieglerTR , WalkerS , et al. The vitamin D for enhancing the immune system in cystic fibrosis (DISC) trial: rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis. Contemporary Clinical Trials Communications2017;6:39-45. [CFGD REGISTER: GN262d] ">Tangpricha 2017</a>) and one looked at a multivitamin with antioxidants but again, not as an antibiotic adjuvant (<a href="./references#CD008037-bbs2-0032" title="JainR , KhanU , BainesA , SagelSD . Biomarkers of inflammation and oxidative stress in CF: implications for antiinflammatory drug development. Pediatric Pulmonology2016;51 Suppl 45:262. [CFGD REGISTER: GN265b] SagelSD , BainesA , AbdulhamidI , BorowitzD , ClancyJP , DainesC , et al. Effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in CF. Pediatric Pulmonology2016;51 Suppl 45:283. [CFGD REGISTER: GN265a] SagelSD , KhanU , JainR , GraffG , DainesCL , DunitzJM , et al. Effects of an antioxidant-enriched multivitamin in cystic fibrosis: randomized, controlled, multicenter trial. American Journal of Respiratory and Critical Care Medicine2018;198(5):639-47. [CFGD REGISTER: GN265c] ">Sagel 2018</a>). One trial looked at the distribution of nebulised solutions in the lungs, but not as an adjuvant therapy (<a href="./references#CD008037-bbs2-0017" title="HodgesL , MacGregorG , StevensH , DessenA , MyrsetA . An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled alginate oligosaccharide delivered as a dry powder and as a nebulised solution in cystic fibrosis patients. Pediatric Pulmonology2014;49 Suppl 38:305. [ABSTRACT NO.: 251] [CENTRAL: 1012384] [CFGD REGISTER: BD215] ">Hodges 2014</a>) and a further trial reported the effect of proton pump inhibition to prevent acid aspiration, not as an antibiotic adjuvant (<a href="./references#CD008037-bbs2-0011" title="DiMangoE , WalkerP , KeatingC , BerdellaM , RobinsonB , Langfelder-SchwindE , et al. Effect of proton pump inhibitors on cystic fibrosis (CF) pulmonary exacerbations in adults [abstract]. Pediatric Pulmonology2012;47 Suppl 35:353, Abstract no: 362. [CENTRAL: 962121] [CFGD REGISTER: GN235a] DimangoE , WalkerP , KeatingC , BerdellaM , RobinsonN , Langfelder-SchwindE , et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulmonary Medicine2014;14:21. [CFGD REGISTER: GN235b] [CTG: NCT01983774] [GR: P30ES009089/ES/NIEHS NIH HHS/United States] [JID: 100968563] [PMCID: PMC3931289] [PMID: 24528942] [UL1: TR000040/TR/NCATS NIH HHS/United States]">DiMango 2014</a>). One trial of glutamine supplementation ws excluded since direct bactericidal activity was expected (<a href="./references#CD008037-bbs2-0013" title="ForresterD , KnoxA , SmythA , BarrH , SimmsR , PaceyS , et al. Glutamine supplementation for cystic fibrosis - a randomised controlled trial. Pediatric Pulmonology2011;46 Suppl 34:288. [ABSTRACT NO.: 214] [CENTRAL: 867950] [CFGD REGISTER: GN231a] ForresterDL , KnoxAJ , SmythAR , BarrHL , SimmsR , PaceySJ , et al. Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial. Pediatric Pulmonology2015;51:253-7. [CFGD REGISTER: GN231b] [DOI: 10.1002/ppul.23370]">Forrester 2015</a>). One trial was excluded because it looked at inhaled dry powder mannitol, but we deemed it to be an adjunct to airway clearance rather than as an antibiotic adjuvant (<a href="./references#CD008037-bbs2-0024" title="MiddletonA , RobinsonP , McKayK , SelvaduraiH . Pilot study of inhaled dry powder mannitol in young people with CF hospitalised with pulmonary exacerbation. Pediatric Pulmonology2012;47 Suppl 35:355. [ABSTRACT NO.: 368] [CENTRAL: 962113] [CFGD REGISTER: BD199a] MiddletonA , RobinsonP , McKayK , SelvaduraiH . Pilot study of inhaled dry powder mannitol in young people with cystic fibrosis hospitalised with pulmonary exacerbation. Department of Respiratory Medicine, Children's Hospital at Westmead (www.thoracic.org.au) (accessed 21 Oct 2014)2014. [CENTRAL: 1012538] [CFGD REGISTER: BD199b] MiddletonA , RobinsonPD , McKayK , JaffeA , SelvaduraiH . A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation [letter]. European Respiratory Journal2015;45(2):541-4. [CENTRAL: 1048444] [CFGD REGISTER: BD199c] [EMBASE: 2015713766]">Middleton 2015</a>). </p> <p>Two trials in participants with an acute respiratory exacerbation were excluded (<a href="./references#CD008037-bbs2-0016" title="HauberH , SchulzM , PforteA , MackD , ZabelP , SchumacherU . Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. International Journal of Medical Sciences2008;5(6):371-6. [CFGD REGISTER: PI268a] [PMID: PMC2586681]PforteA , Hauber HP , MackD , SchumacherU . Inhalation with Fucose and Galactose a new therapeutic approach in adult cystic fibrosis patients with Pseudomonas aeruginosa-Infection [Inhalation mit Fucose und Galactose als neuer Therapieansatz bei erwachsenen Mukoviszidosepatienten mit Pseudomonas aeruginosa-Infektion]. Pneumologie (Stuttgart, Germany)2001;55(SH1):S68. [CENTRAL: 402236] [CFGD REGISTER: PI268b] ">Hauber 2008</a>; <a href="./references#CD008037-bbs2-0035" title="WinnieGB , CowanRG , WadeNA . Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. Journal of Pediatrics1989;114(2):309-14. [CFGD REGISTER: PI224] [DOI: 10.1016/S0022-3476(89)80804-2]">Winnie 1989</a>). One trial randomised participants to receive either inhaled sugars (inhaled fucose and galactose) for treating their pulmonary exacerbation or inhaled sugars accompanied by IV antibiotics (<a href="./references#CD008037-bbs2-0016" title="HauberH , SchulzM , PforteA , MackD , ZabelP , SchumacherU . Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. International Journal of Medical Sciences2008;5(6):371-6. [CFGD REGISTER: PI268a] [PMID: PMC2586681]PforteA , Hauber HP , MackD , SchumacherU . Inhalation with Fucose and Galactose a new therapeutic approach in adult cystic fibrosis patients with Pseudomonas aeruginosa-Infection [Inhalation mit Fucose und Galactose als neuer Therapieansatz bei erwachsenen Mukoviszidosepatienten mit Pseudomonas aeruginosa-Infektion]. Pneumologie (Stuttgart, Germany)2001;55(SH1):S68. [CENTRAL: 402236] [CFGD REGISTER: PI268b] ">Hauber 2008</a>). While these agents are specific substrates for the galactophilic and fucophilic lectins (cell surface proteins involved in bacterial aggregation) which are known in vitro to inhibit aggregation and promote dispersal of <i>P aeruginosa</i> biofilms (<a href="./references#CD008037-bbs2-0049" title="JohanssonEM ,  CruszSA ,  KolomietsE ,  ButsL ,  KadamRU ,  CacciariniM , et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chemistry and Biology2008;15(12):1249-57. [DOI: 10.1016/j.chembiol.2008.10.009]">Johansson 2008</a>), these agents have a novel non‐osmotic mechanism of action. While the trial was not immediately excluded, further assessment ascertained that there was no true control group and it was therefore excluded (<a href="./references#CD008037-bbs2-0016" title="HauberH , SchulzM , PforteA , MackD , ZabelP , SchumacherU . Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. International Journal of Medical Sciences2008;5(6):371-6. [CFGD REGISTER: PI268a] [PMID: PMC2586681]PforteA , Hauber HP , MackD , SchumacherU . Inhalation with Fucose and Galactose a new therapeutic approach in adult cystic fibrosis patients with Pseudomonas aeruginosa-Infection [Inhalation mit Fucose und Galactose als neuer Therapieansatz bei erwachsenen Mukoviszidosepatienten mit Pseudomonas aeruginosa-Infektion]. Pneumologie (Stuttgart, Germany)2001;55(SH1):S68. [CENTRAL: 402236] [CFGD REGISTER: PI268b] ">Hauber 2008</a>)<i>.</i> The second trial examined the effect of immunoglobulin on the treatment of pulmonary exacerbations and was excluded since it was a trial of immunotherapy (<a href="./references#CD008037-bbs2-0035" title="WinnieGB , CowanRG , WadeNA . Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. Journal of Pediatrics1989;114(2):309-14. [CFGD REGISTER: PI224] [DOI: 10.1016/S0022-3476(89)80804-2]">Winnie 1989</a>). </p> </section> <section id="CD008037-sec-0050"> <h4 class="title">Trials awaiting classification</h4> <p>Six trials are listed as 'Awaiting classification' (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>; <a href="./references#CD008037-bbs2-0037" title="BoskabadyM , Nemat KhorasaniE , MansouriF , SoltanianE , BoskabadyM . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Journal of Research in Medical Sciences2012;17(12):jrms.mui.ac.ir/index.php/jrms/article/view/8833. KhorasaniEN , MansouriF . Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. In: Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria. 2009:722s. [ABSTRACT NO.: P4032] [CENTRAL: 793188] [CFGD REGISTER: GN255] ">Khorasani 2009</a>; <a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a>; <a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>; <a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>; <a href="./references#CD008037-bbs2-0041" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects. clinicaltrials.gov/ct2/show/NCT00928135 (first received 25 June 2009). ">Zabner 2009</a>). </p> <p>Two cross‐over RCTs of OligoG have been completed but we are awaiting first‐arm data (<a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>; <a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>). OligoG is an oligosaccharide derived from alginate polysaccharide. It is suggested that this disrupts bacterial biofilm formation (a mode of bacterial growth associated with antibiotic tolerance and resistance). One RCT includes 12 participants with CF who also have chronic <i>Burkholderia sp.</i> infection; inhaled OligoG is given for 28 days to look at the effect on lung function, QoL, sputum rheology and microbiological outcomes (<a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>). The second RCT includes 26 participants aged 18 or over who have <i>P aeruginosa</i> in expectorated sputum. Inhaled OligoG was compared to saline to look at safety and tolerability (<a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>). </p> <p>The third trial awaiting classification is looking at the effect of zinc on lung function, the rate of respiratory infections and the need for antibiotics; it is unclear at this stage whether it is randomised as it is only presented as an abstract. It includes 20 children with CF between seven and 18 years (<a href="./references#CD008037-bbs2-0037" title="BoskabadyM , Nemat KhorasaniE , MansouriF , SoltanianE , BoskabadyM . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Journal of Research in Medical Sciences2012;17(12):jrms.mui.ac.ir/index.php/jrms/article/view/8833. KhorasaniEN , MansouriF . Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. In: Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria. 2009:722s. [ABSTRACT NO.: P4032] [CENTRAL: 793188] [CFGD REGISTER: GN255] ">Khorasani 2009</a>). </p> <p>A further trial awaiting assessment has six arms comparing five different doses of oral cysteamine (Lynovex®) to placebo over 14 days (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>). It is multicentre and double‐blind and has recruited 89 adults with CF experiencing an acute exacerbation. Investigators are assessing the change in sputum bacterial load, QoL, blood leukocyte count, adverse events and serious adverse events, the change from baseline in sputum neutrophil elastase and IL‐8 levels, in FEV<sub>1</sub>, in weight and in BMI. To date some information has been published in abstract form and we are awaiting the publication of the full trial before including or excluding the trial (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>). </p> <p>One trial compared calcium ethylene diamine tetra‐acetate to saline in 24 people with CF with chronic <i>P aeruginosa</i> infection (<a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a>). For the initial two weeks, treatment was administered four times daily in conjunction with antibiotics; following this treatment was administered twice daily for a further two weeks and finally a four‐week safety follow‐up period. Investigators planned to assess the mean <i>P aeruginosa</i> sputum count, FEV<sub>1</sub> % predicted and adverse events. Again, this trial has only been published in abstract form and we are awaiting the publication of the full trial before including or excluding the trial (<a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a>). </p> <p>The final trial listed as 'Awaiting classification' is a double‐blind, parallel RCT in people with CF aged 16 or older (<a href="./references#CD008037-bbs2-0041" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects. clinicaltrials.gov/ct2/show/NCT00928135 (first received 25 June 2009). ">Zabner 2009</a>). It compares hypertonic xylitol with hypertonic saline in terms of lung function, adverse events, respiratory symptoms, density of colonisation and time to exacerbations. The putative mechanism of action is a reduction in airway surface liquid salt concentration, thus facilitating lysozyme and β‐defensins' protective action. One of the trials excluded on the basis of non‐randomisation (<a href="./references#CD008037-bbs2-0012" title="DurairajL , LaunspachJ , WattJL , MohamadZ , KlineJ , ZabnerJ . Safety assessment of inhaled xylitol in subjects with cystic fibrosis. Journal of Cystic Fibrosis 2007 Jan;6(1):31-4. ">Durairaj 2007</a>) is a pre‐cursor to this trial; the trial has now been completed but the results are not yet available (<a href="./references#CD008037-bbs2-0041" title="NCT00928135. Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects. clinicaltrials.gov/ct2/show/NCT00928135 (first received 25 June 2009). ">Zabner 2009</a>). </p> </section> <section id="CD008037-sec-0051"> <h4 class="title">Ongoing trials</h4> <p>We will assess the ongoing trial for inclusion in the review when it is completed and results available (<a href="./references#CD008037-bbs2-0042" title="DaviesJ . Oligo G: a novel mucolytic from basic science to clinical trials. Pediatric Pulmonology2017;52 Suppl 47:150-1. [CFGD REGISTER: BD235c] DonaldsonSH , BennettWD , ZemanK , PresslerT , GowL , ConwayJ , et al. A first in class mucus conditioning drug-effect of an inhaled alginate oligosaccharide (oligo-g) on mucus clearance in subjects with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:305. [CFGD REGISTER: BD235d] PresslerT , DonaldsonS , SmerudKT , MyrsetAH , OligoG Study Team. A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 1:S1. [CFDG REGISTER: BD235b] PresslerT , DonaldsonSH , DaviesJC , Hilde MyrsetA . A double-blind, randomised, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) administered for 28 days in subjects with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl:271. [CFGD REGISTER: BD235a] PresslerT . A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984). Clinicaltrials.gov August 2016. ">Pressler 2017</a>). It is a double‐blind, cross‐over RCT looking at the effects of OligoG in 76 adults with CF and <i>P aeruginosa</i> in expectorated sputum. OligoG is given via inhalation compared to placebo and the outcomes include FEV<sub>1</sub>, mucociliary clearance, rheology, microbiology and QoL (<a href="./references#CD008037-bbs2-0042" title="DaviesJ . Oligo G: a novel mucolytic from basic science to clinical trials. Pediatric Pulmonology2017;52 Suppl 47:150-1. [CFGD REGISTER: BD235c] DonaldsonSH , BennettWD , ZemanK , PresslerT , GowL , ConwayJ , et al. A first in class mucus conditioning drug-effect of an inhaled alginate oligosaccharide (oligo-g) on mucus clearance in subjects with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:305. [CFGD REGISTER: BD235d] PresslerT , DonaldsonS , SmerudKT , MyrsetAH , OligoG Study Team. A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 1:S1. [CFDG REGISTER: BD235b] PresslerT , DonaldsonSH , DaviesJC , Hilde MyrsetA . A double-blind, randomised, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) administered for 28 days in subjects with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl:271. [CFGD REGISTER: BD235a] PresslerT . A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984). Clinicaltrials.gov August 2016. ">Pressler 2017</a>). </p> </section> </section> <section id="CD008037-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>We did not identify any trials undertaken during acute respiratory exacerbations; all the following information relates to trials in participants with chronic infection. The risk of bias summary figure summarises these judgements (<a href="#CD008037-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008037-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008037-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD008037-sec-0053"> <h4 class="title">Allocation</h4> <section id="CD008037-sec-0054"> <h5 class="title">Generation of sequence</h5> <p>We deemed four trials to be at low risk of bias for this domain (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). In one of the NO trials the sequence was generated by an online randomisation service (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). One of the KB001‐A trials used an interactive web response system (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>) and one of the zinc trials used computer‐generated randomisation carried out by a person not involved in the trial (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). The garlic trial used a web‐based random allocation system provided by an external agency (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> <p>We judged four trials to have an unclear risk of bias (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). The β‐carotene trial was described as 'randomised', unfortunately the randomisation method is not described (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). In the second zinc trial, the assignment of participants to the treatment group was reported to have occurred 'randomly', but no methods are described (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>); this is also the case with the remaining KB001‐A trial (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The second NO trial claimed to be randomised but no description of the randomisation process was given (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </section> <section id="CD008037-sec-0055"> <h5 class="title">Allocation concealment</h5> <p>We deemed four trials to be at low risk of bias for allocation concealment (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). The Howlin NO trial stated that randomisation was undertaken via an online randomisation service to ensure concealment of treatment allocation (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). The Jain KB001‐A trial stated that the drug assignment was conducted via an interactive web response system (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). In the Sharma zinc trial, the drugs were labelled sequentially and put into sealed opaque envelopes by a person not involved in the trial (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). The authors of the garlic trial confirmed that the garlic supplements were dispensed in coded opaque sealed containers (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> <p>The remaining four trials did not provide details on allocation concealment so we judged the risk of bias to be unclear; the β‐carotene trial (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>); one of the zinc trials (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>); one of the KB001‐A trials (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>); and one of the NO trials (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </section> </section> <section id="CD008037-sec-0056"> <h4 class="title">Blinding</h4> <p>We judged seven of our eight included trials to have a low risk of bias due to blinding (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). Both NO trials were described as double‐blinded with NO and placebo being given via nasal cannulae so that participants were not able to differentiate between treatments (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). Similarly, both KB001‐A trials reported that they were double‐blind and IV infusion bags were labelled to maintain blinding (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). In the β‐carotene trial, the supplement was reported as being identical to a starch‐containing placebo (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). The garlic trial detailed the flavour masking agent, described both active and placebo agents as identical and reported participant guesses of which treatment they thought they had received (no significant difference) (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). One of the zinc trials administered similar looking zinc or placebo tablets to the children (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <p>The remaining zinc supplement trial detailed that the two groups were given either zinc gluconate or placebo preparations in capsules. The appearance of these capsules was unreported and so we judge the risk of bias to be unclear (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> </section> <section id="CD008037-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four trials to have a low risk of bias due to incomplete outcome data (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). One NO trial reported that all 12 participants completed the trial and were included in the analysis (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). The β‐carotene trial reports end results for all 24 participants identified in the methods section (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). One zinc trial carried out a ITT analysis as well as a per protocol analysis and only three participants withdrew consent (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). The garlic trial randomised 34 participants of whom eight withdrew: four in the garlic group (one received lung transplant, one forgot to take capsules, one withdrew due to indigestion and one could not attend the second visit); and four in the placebo group (two forgot to take capsules, one withdrew due to halitosis and one could not attend the second visit). Furthermore, data for the primary outcome (lung function) were missing for one participant in the placebo arm; analysis was per protocol (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> <p>We judged three trials to have an unclear risk of attrition bias (both KB001‐A trials and one NO trial) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). Jain used a modified ITT analysis where any participant who had received three doses of the trial drug were included in the analysis; however, from the original 182 participants randomised, five withdrew from the placebo group before the start of treatment and eight from the KB001‐A group. A further 15 participants from the placebo group and 21 from the KB001‐A group withdrew before the end of the trial but no reasons were given (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). Of the 27 participants randomised in the Milla trial, two participants discontinued the trial due to infusion‐related AEs (one from each of the KB001‐A groups) and a further three participants were excluded from the analysis as they received prohibited medications (two from the KB001‐A 3 mg/kg group and one from the placebo group). As the number of participants dropping out is more than 15%, we judged the risk of attrition bias to be unclear (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Although all 18 participants remained in the Sagel inhaled NO trial, one participant was given both NO and nitrogen and the authors state that they removed these data from their analysis. However, the data reported in the clinical trials registration document is for 18 participants, therefore it is not clear whether the data were removed for this participant or not; for this reason we judged the risk of attrition bias to be unclear (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <p>The second zinc trial randomised 13 children to each group, but one participant in the treatment group withdrew from the trial and it is unclear whether this person was included in the final analysis (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). We therefore judged there to be a high risk of bias since the incomplete outcome data were not addressed. </p> </section> <section id="CD008037-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Six trials were judged to have a low risk of selective reporting bias (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). We did not identify any evidence of selective outcome reporting in the Jain trial after comparing the protocol and the trial report (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). We compared the published protocols of one of the KB001‐A trials and the garlic trial to the trial publications and no issues of selective reporting were identified (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). In the Sharma trial, all outcomes stated in the methods section of the trial report are reported in the results section (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). The β‐carotene trial does not have a registration on a clinical trials registry making it difficult to determine the primary outcome measures; however, the impact of any bias due to this is likely to be minimal (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). When considered in isolation, the individual publications of the β‐carotene trial each suffer from selective reporting as a result of duplicate publications with differing emphasis. The post hoc analysis describing an effect upon FEV<sub>1</sub> in the 'younger' participants suffers from selective reporting as only data for the treatment group are described. However, with the post hoc analysis issue aside, when the individual reports are considered together, the results appear to not suffer from selective reporting (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). </p> <p>One of the zinc trials suffers considerably from selective reporting in the original paper (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). The groups were originally assigned to one of the two trial arms 'randomly' without respect to their prior zinc status; however, the outcomes of these participants are reported in terms of prior zinc status. Investigators reported zinc status using a threshold of normal far below what is considered by their institutions' laboratory to be normal. Indeed, they later state that their groups had normal zinc levels within the clinically acceptable normal range and justify their use of a higher range of 'normal' zinc level by citing their own previous work which reports that those with lower zinc levels are more susceptible to infections. The protocol lists lung function as an outcome measure, but this is not reported in the original paper (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). We therefore initially judged the risk of selective outcome reporting bias to be high; however, the authors have provided the raw data without reference to prior zinc status, which has reduced our interpretation of the bias introduced to low. </p> <p>We deemed the remaining two trials of NO to have an unclear risk of bias for selective outcome reporting (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). In the Howlin trial, not all of the outcomes specified in the trial registration document and methods section of the paper were reported in the paper's results (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). In the second NO trial not all of the outcomes listed in the methods section of the paper were reported in the results (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </section> <section id="CD008037-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We considered compliance to treatment, but in three trials we judged compliance not to be an issue (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). In the safety trial of KB001‐A compliance is not an issue as this was a trial of a one‐dose infusion; this trial was sponsored by the pharmaceutical company developing KB001‐A (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Compliance was also not identified as a potential risk of bias in the NO trials as the intervention was administered in hospital (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <p>We judged there to be a low risk of bias with regards to compliance in three trials (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). We found no source of bias relating to compliance in the Jain trial (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). One of the zinc trials measured adherence by capsule counting of returned medication and was deemed to be at a low risk of other potential bias (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). In the Smyth trial, compliance to the garlic protocol was assessed by participant report and capsule counting; this was reported as equal and so we judged the risk of bias to be low (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> <p>In the remaining two trials the risk of bias from compliance was judged to be unclear (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). Compliance to the zinc trial protocol for the was reported only in terms of prior zinc status and the per protocol analysis of compliance is not provided (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). Compliance to the β‐carotene protocol was assessed by participant report and capsule counting; however, the result was not reported (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). </p> </section> </section> <section id="CD008037-sec-0060"> <h3 class="title" id="CD008037-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD008037-tbl-0001"><b>Summary of findings 1</b> Summary of findings: β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</a>; <a href="./full#CD008037-tbl-0002"><b>Summary of findings 2</b> Summary of findings: garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</a>; <a href="./full#CD008037-tbl-0003"><b>Summary of findings 3</b> Summary of findings: monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</a>; <a href="./full#CD008037-tbl-0004"><b>Summary of findings 4</b> Summary of findings: nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</a>; <a href="./full#CD008037-tbl-0005"><b>Summary of findings 5</b> Summary of findings: Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</a> </p> <p>The effects of interventions are summarised in the summary of findings tables, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings provided (<a href="./full#CD008037-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008037-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008037-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008037-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD008037-tbl-0005">summary of findings Table 5</a>). </p> <section id="CD008037-sec-0061"> <h4 class="title">Acute respiratory exacerbations</h4> <p>There were no trials included which considered acute respiratory exacerbations.</p> </section> <section id="CD008037-sec-0062"> <h4 class="title">Chronic infection</h4> <p>All eight included trials investigated antibiotic adjuvant therapies for chronic pulmonary infection (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). For simplicity we have reported below only the review's outcome measures that have been reported in the selected trials. </p> <section id="CD008037-sec-0063"> <h5 class="title">β‐carotene supplementation</h5> <p>One trial (n = 24) compared β‐carotene supplementation to placebo (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). </p> <section id="CD008037-sec-0064"> <h6 class="title">Primary outcomes</h6> <section id="CD008037-sec-0065"> <p><b>1. Pulmonary exacerbations (protocol defined)</b></p> <p>Investigators report a reduced rate of pulmonary exacerbations in the treatment arm, defined as the number of days of antibiotic consumption, although this is not statistically significant, MD ‐8.00 (95% CI ‐18.78 to 2.78) (<a href="./references#CD008037-fig-0003" title="">Analysis 1.1</a>). We judged the quality of evidence for this outcome to be low. </p> </section> <section id="CD008037-sec-0066"> <p><b>2. Respiratory function</b></p> <p>a. FEV<sub>1</sub> % predicted </p> <p>There appeared to be no effect upon lung function (FEV<sub>1</sub> % predicted) between the two groups, MD ‐10.90% (95% CI ‐32.23% to 10.43%) (<a href="./references#CD008037-fig-0004" title="">Analysis 1.2</a>). The authors describe an apparently post hoc analysis of the 'younger patients' (undefined) and suggest their FEV<sub>1</sub> 'clearly improved'. Unfortunately only data for the treatment group are presented. We judged the quality of evidence for this outcome to be low. </p> <p>b. FVC % predicted</p> <p>This outcome was measured but not reported per protocol. The authors state that mean (SD) FVC did not change during the treatment (baseline 87.6% predicted (21.2%), week 12 85.1% predicted (24.6%) and week 24 85.6% predicted (25.1%)) (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). </p> </section> <section id="CD008037-sec-0067"> <p><b>3. Adverse events</b></p> <p>There were no adverse events reported during the trial, but some participants reported better tanning after exposure to sunlight (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). We judged the quality of evidence for this outcome to be low. </p> </section> </section> <section id="CD008037-sec-0068"> <h6 class="title">Secondary outcomes</h6> <section id="CD008037-sec-0069"> <p><b>1. Antibiotic consumption</b></p> <p>b. As above, the protocol definition of pulmonary exacerbation was the antibiotic consumption rate in days (<a href="./references#CD008037-fig-0003" title="">Analysis 1.1</a>) (low‐quality evidence). </p> </section> <section id="CD008037-sec-0070"> <p><b>5. Mortality</b></p> <p>There were no dropouts during the trial and so we assume that no deaths occurred, although this was not explicitly discussed (<a href="./references#CD008037-fig-0005" title="">Analysis 1.3</a>). </p> </section> </section> </section> <section id="CD008037-sec-0071"> <h5 class="title">Garlic supplementation</h5> <p>One included trial (n = 34) investigated garlic supplementation (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). There were no statistically significant changes in clinical score and lung function. It was also not possible to detect a difference in quorum sensing molecules in plasma or sputum. </p> <section id="CD008037-sec-0072"> <h6 class="title">Primary outcomes</h6> <section id="CD008037-sec-0073"> <p><b>2. Respiratory function</b></p> <p>a. FEV<sub>1</sub> % predicted </p> <p>The percentage change in % predicted FEV<sub>1</sub> between the treated and control groups did not reach significance, MD 1.59% predicted (95% CI ‐7.49% to 10.67%) (<a href="./references#CD008037-fig-0006" title="">Analysis 2.1</a>). We judged the quality of evidence to be moderate. </p> </section> <section id="CD008037-sec-0074"> <p><b>3. Adverse events</b></p> <p>a. mild (not requiring treatment)</p> <p>Five participants in each group had abnormal liver function or triglyceride levels. Five participants in the garlic group reported minor adverse effects (diarrhoea (two participants), halitosis (two participants), abdominal pain (one participant), dysuria (one participant), minor haemoptysis (one participant)). One participant from the placebo group reported a minor haemoptysis (<a href="./references#CD008037-fig-0008" title="">Analysis 2.3</a>). We again judged the quality of evidence to be moderate. </p> </section> </section> <section id="CD008037-sec-0075"> <h6 class="title">Secondary outcomes</h6> <section id="CD008037-sec-0076"> <p><b>2. Antibiotic consumption (days of antibiotic use)</b></p> <p>Seven participants in the garlic group received intravenous antibiotics compared to five in the placebo group; however, days of antibiotic use was not reported (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> </section> <section id="CD008037-sec-0077"> <p><b>5. Mortality</b></p> <p>There were no deaths during the trial period (<a href="./references#CD008037-fig-0007" title="">Analysis 2.2</a>). </p> </section> </section> </section> <section id="CD008037-sec-0078"> <h5 class="title">KB001‐A</h5> <p>Two trials compared KB001‐A to placebo (n = 196) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). One trial was single‐dose trial (n = 27) with participants followed up for eight weeks (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>), whilst the second trial (n = 169) administered KB001‐A via infusion once every four weeks over a 16‐week period (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). For this reason we could not combine the results in a meta‐analysis. </p> <section id="CD008037-sec-0079"> <h6 class="title">Primary outcomes</h6> <section id="CD008037-sec-0080"> <p><b>1. Pulmonary exacerbations (protocol defined)</b></p> <p>In the single‐dose trial investigators reported the number of CF exacerbations (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). No participants experienced a CF exacerbation after the 10 mg/kg dose of KB001‐A, one participant who received a 3 mg/kg dose of KB001‐A experienced a pulmonary exacerbation and there were two reports of pulmonary exacerbations in the placebo group, RR 0.25 (95 % CI 0.03 to 2.40) (<a href="./references#CD008037-fig-0009" title="">Analysis 3.1</a>). </p> <p>Jain did not report pulmonary exacerbations as a primary outcome, but found that an infective pulmonary exacerbation was the most common adverse event in both groups (57.8% of KB001‐A participants and 67.4% of placebo participants) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> <p>The GRADE assessment for this outcome was judged to be low.</p> <p><i>2. Respiratory function</i> </p> <p>a. FEV<sub>1</sub> % predicted </p> <p>Milla reports the number of episodes of a drop in lung function (FEV<sub>1</sub>, unit of measurement not given); however, the lung function data in terms of the size of decrease in FEV<sub>1</sub> are not reported (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Six participants who received a 3 mg/kg dose of KB001‐A experienced a decrease in FEV<sub>1</sub>, RR 4.74 (95% CI 0.28 to 79.44) (<a href="./references#CD008037-fig-0010" title="">Analysis 3.2</a>). </p> <p>In the trial of KB001‐A given over a longer period, the authors reported a 3% increase in the absolute change from baseline in % predicted FEV<sub>1</sub> at week 16 for the KB001‐A arm versus placebo, MD 3.2% (95% CI 1.12% to 5.30%) (P = 0.003) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> <p>We judged the GRADE assessment for this outcome to be very low.</p> <p>b. FVC % predicted</p> <p>Milla found no significant differences between active treatment and placebo groups for FVC (unit not stated) at any time point (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>c. Other validated measures of respiratory function</p> <p>Milla also found no significant differences between active treatment and placebo groups for any other spirometry parameters (FEF<sub>25-75</sub>) at any time point (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> </section> <section id="CD008037-sec-0081"> <p><b>3. Adverse events</b></p> <p>The primary outcome of the Milla trial was the number of participants experiencing adverse events. Seven of those who received placebo and all (n = 18) of those who received KB001‐A experienced an adverse event, RR 1.30 (95% CI 0.90 to 1.87) (<a href="./references#CD008037-fig-0011" title="">Analysis 3.3</a>). </p> <p>There is insufficient information to determine the severity of the events according to our classification of mild, moderate and severe, we have therefore used the classification reported in the trial ‐ 'serious' and 'other'. The trial reports the following serious adverse effects: a participant receiving a 3 mg/kg dose of KB001‐A developed bronchitis, RR 1.58 (95% CI 0.07 to 35.32); and a participant who received placebo developed sinusitis, RR 0.18 (95% CI 0.01 to 3.92) (<a href="./references#CD008037-fig-0012" title="">Analysis 3.4</a>). The 'other' events are described under group headings and presented in the analyses (<a href="./references#CD008037-fig-0013" title="">Analysis 3.5</a>; <a href="./references#CD008037-fig-0014" title="">Analysis 3.6</a>; <a href="./references#CD008037-fig-0015" title="">Analysis 3.7</a>; <a href="./references#CD008037-fig-0016" title="">Analysis 3.8</a>; <a href="./references#CD008037-fig-0017" title="">Analysis 3.9</a>; <a href="./references#CD008037-fig-0018" title="">Analysis 3.10</a>; <a href="./references#CD008037-fig-0019" title="">Analysis 3.11</a>; <a href="./references#CD008037-fig-0020" title="">Analysis 3.12</a>; <a href="./references#CD008037-fig-0021" title="">Analysis 3.13</a>; <a href="./references#CD008037-fig-0022" title="">Analysis 3.14</a>; <a href="./references#CD008037-fig-0023" title="">Analysis 3.15</a>). </p> <p>Jain reported no treatment‐emergent adverse events and similar numbers of participants with infusion reactions between intervention and placebo. The number of hospitalised participants was higher in the KB001‐A group compared to placebo (28.9% versus 16.3%) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> <p>Again, we judged the GRADE assessment of quality to be very low.</p> </section> </section> <section id="CD008037-sec-0082"> <h6 class="title">Secondary outcomes</h6> <section id="CD008037-sec-0083"> <p><b>1. Need for antibiotics</b></p> <p>a. Time to next course of antibiotics (oral, inhaled or IV)</p> <p>The Jain trial found no difference in the time to need for antibiotics in the KB001‐A group versus placebo over the 16‐week period, HR 1.00 (95% CI 0.69 to 1.45) (result taken directly from the paper) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). We deemed the quality of this evidence to be moderate. </p> </section> <section id="CD008037-sec-0084"> <p><b>2. QoL</b></p> <p>b. Treatment burden</p> <p>Milla looked at change in CFQ‐R scores but found no significant differences between groups at any time point (data not given) (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Similarly, Jain measured change in respiratory symptom scores from baseline using the CFRSD‐CRISS symptom severity score, but found no difference between treatment groups (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). We rated the quality of evidence as low for this outcome. </p> </section> <section id="CD008037-sec-0085"> <p><b>3. Change in sputum microbiology</b></p> <p>b. Quantitative microbiology</p> <p>At day 28 there was a numerical reduction from baseline in median mucoid <i>P aeruginosa</i> density in the KB001‐A 10 mg/kg group (‐0.4 log<sub>10</sub>) compared to placebo (0.8 log<sub>10</sub>) but the changes were not significant (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). We deemed the quality of this evidence to be low. </p> </section> <section id="CD008037-sec-0086"> <p><b>4. Change in inflammatory markers</b></p> <p>Milla reported no significant changes in biomarkers from baseline, but there was a trend towards a KB001‐A dose‐dependent reduction in sputum myeloperoxidase, IL‐8, IL‐1β and neutrophil elastase (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Jain reported a ‐0.24 log<sub>10</sub> reduction in IL‐8 in the KB001‐A group compared to placebo at week 16 (P = 0.04), but the decrease in sputum neutrophil elastase (NE) was not significant, MD ‐0.27 (95% CI ‐0.58 to 0.04; P = 0.084) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). The quality of this evidence was found to be very low. </p> </section> <section id="CD008037-sec-0087"> <p><b>5. Mortality</b></p> <p>Milla reported no deaths during the trial (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> </section> </section> </section> <section id="CD008037-sec-0088"> <h5 class="title">Nitric oxide</h5> <p>Two trials (n = 30) reported on the effect of inhaled NO as an antibiotic adjuvant, but the data cannot be combined in a meta analysis because one trial administered NO at 10 ppm for eight hours overnight for five to seven days (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>), whilst the second trial administered NO continuously for 44 hours at doses of either 20 or 40 ppm (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <section id="CD008037-sec-0089"> <h6 class="title">Primary outcomes</h6> <section id="CD008037-sec-0090"> <p><b>2. Respiratory function</b></p> <p>a. FEV<sub>1</sub> % predicted </p> <p>Howlin reported a greater increase in FEV<sub>1</sub> % predicted in the placebo group compared to the inhaled NO group but this was not significant after 20 days (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>), MD ‐1.95 (95% CI ‐9.94 to 6.04) (P = 0.63) (<a href="./references#CD008037-fig-0024" title="">Analysis 4.1</a>). The Sagel trial only reported a value for baseline FEV<sub>1</sub> (L) for each group and a value after 48 hours, but no statistics were given (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). We graded the quality of evidence as low. </p> <p>b. FVC % predicted</p> <p>This was only reported in the Howlin trial which found that after five to seven days of inhaled NO or placebo gas, there was a greater (non‐significant) change from baseline in FVC % predicted in the placebo group compared to the NO group, MD ‐8.03 (95 % CI ‐18.50 to 2.44) (P = 0.13) (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> </section> <section id="CD008037-sec-0091"> <p><b>3. Adverse events</b></p> <p>Both trials reported adverse events but numbers were low. Howlin reported that in the NO group four participants reported adverse events including epistaxis, cough and cold, increased cough and haemoptysis, but all events were considered mild and only possibly related to the trial treatment. In the placebo group only one adverse event was reported, which was epistaxis (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). Sagel reported no serious adverse events in either the NO group or the placebo group at either the low or high dose of NO (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). We rated the quality of evidence as very low for this outcome. </p> </section> </section> <section id="CD008037-sec-0092"> <h6 class="title">Secondary outcomes</h6> <section id="CD008037-sec-0093"> <p><b>3. Change in sputum microbiology</b></p> <p>b. Quantitative microbiology</p> <p>Howlin found that there was a significant reduction in <i>P aeruginosa</i> biofilm aggregates compared with those receiving placebo with antibiotics over the seven‐day treatment period (P = 0.029) and there was less <i>P aeruginosa</i> biofilm in the NO group compared with placebo (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). Sagel reported that there was a significant reduction in <i>S aureus</i> colony counts in the high‐dose NO group compared to placebo (P = 0.03) and a near significant reduction in <i>P aeruginosa</i> colony counts in the high‐dose group compared to placebo (P = 0.06) (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). Again, we rated the quality of this evidence as very low. </p> </section> </section> </section> <section id="CD008037-sec-0094"> <h5 class="title">Zinc supplementation</h5> <p>Two trials (n = 66) compared zinc supplementation to placebo (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <section id="CD008037-sec-0095"> <h6 class="title">Primary outcomes</h6> <section id="CD008037-sec-0096"> <p><b>1. Pulmonary exacerbations (protocol‐defined)</b></p> <p>Investigators in the Abdulhamid trial do not report on their protocol definition of an exacerbation; they only report the number of episodes requiring IV and oral antibiotics (see results below) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). In the Sharma trial, the authors report on the number of participants requiring IV antibiotics during the treatment phase. Seven participants (38.9%) in the zinc group and four participants (20.1%) in the placebo group experienced exacerbations requiring IV antibiotics during the 12‐month trial, RR 1.85 (95% CI 0.65 to 5.26) (<a href="./references#CD008037-fig-0026" title="">Analysis 5.1</a>); this result is not statistically significant (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). We graded the quality of evidence as moderate. </p> </section> <section id="CD008037-sec-0097"> <p><b>2. Respiratory function</b></p> <p>a. FEV<sub>1</sub> % predicted<br/>Abdulhamid presents this measure in the baseline characteristics, but the outcome is not reported post‐treatment in the published paper (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). After contacting the authors, we received the data to allow us to analyse this outcome in the graphs and these showed no difference between groups, MD ‐5.46 (95% CI ‐19.44 to 8.52) (<a href="./references#CD008037-fig-0031" title="">Analysis 5.6</a>). </p> <p>Sharma measured the change in FEV<sub>1</sub> % predicted and reported the median and interquartile range (IQR); thus we were not able to combine the results of the two trials. Sharma found that the median (IQR) FEV<sub>1</sub> % predicted was 8.97% (‐18.23 to 0.33) lower than baseline in the zinc group and 9.55% (‐9.59 to 12.88) higher in the placebo group (P = 0.08). </p> <p>We judged the quality of this evidence to be very low.</p> <p>b. FVC % predicted<br/>Only the Abdulhamid trial reported this outcome; again, the measure was presented in the baseline characteristics, but not reported in the published paper (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). Dr Abdulhamid supplied data for analysis and these showed a statistically non‐significant difference between groups, MD ‐1.75 (95% CI ‐13.09 to 9.59) (<a href="./references#CD008037-fig-0027" title="">Analysis 5.2</a>). </p> </section> <section id="CD008037-sec-0098"> <p><b>3. Adverse events</b></p> <p>Abdulhamid reported no adverse events (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). Sharma reported 15 serious adverse events or hospitalisations in 13 participants; all of the serious adverse events were related to exacerbations (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). Seven children were hospitalised in the zinc group compared to six in the placebo group, RR 1.23 (95% CI 0.51 to 2.97) (P = 0.64) (<a href="./references#CD008037-fig-0032" title="">Analysis 5.7</a>). We judged to quality of evidence for this outcome to be moderate. </p> </section> </section> <section id="CD008037-sec-0099"> <h6 class="title">Secondary outcomes</h6> <section id="CD008037-sec-0100"> <p><b>2. Antibiotic consumption (days of antibiotic use)</b></p> <p>Additional data for one trial (provided by the investigators) showed that zinc supplementation resulted in a statistically significant reduction in the number of days of oral antibiotics alone, MD ‐17.74 (95% CI ‐26.98 to ‐8.50) (P = 0.05) (<a href="./references#CD008037-fig-0028" title="">Analysis 5.3</a>) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). However, the difference between groups was not statistically significant for duration of IV antibiotics, MD 0.52 (95% CI ‐3.07 to 4.11) (<a href="./references#CD008037-fig-0029" title="">Analysis 5.4</a>). When the data for both oral and IV antibiotics combined, as supplied by Dr Abdulhamid, were analysed these showed a statistically significant difference between treatment and control groups, MD ‐17.22 (95% CI ‐27.06 to ‐7.38) (<a href="./references#CD008037-fig-0030" title="">Analysis 5.5</a>). </p> <p>The Sharma trial reported the median (range) number of days of oral or IV antibiotics, but found no significant difference between groups. The median (range) in the zinc group was 42 days (0 to 238) and in the placebo group 38 days (0 to 224) (P = 0.76) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> <p>We judged the quality of this outcome to be very low.</p> </section> <section id="CD008037-sec-0101"> <p><b>5. Mortality</b></p> <p>Sharma reported that none of the participants died during the trial (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008037-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008037-sec-0102"></div> <section id="CD008037-sec-0103"> <h3 class="title" id="CD008037-sec-0103">Summary of main results</h3> <p>We identified eight RCTs with 350 participants from our systematic search of the literature (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). The trials looked at the effects of five different interventions compared with placebo: β‐carotene; garlic; monoclonal antibody KB001‐A; NO; and zinc supplementation. Neither the trial of β‐carotene supplementation or the trial of garlic supplementation detected a statistically significant difference between those in the treatment and control groups for any outcome measure (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). Similarly, the trials of KB001‐A found no significant difference in exacerbations and we are uncertain as to the effect on FEV<sub>1</sub>; there is also probably no difference in time to need for antibiotics between KB001‐A and placebo (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The earlier trial of KB001‐A was a safety trial with limited data published online (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>), but this led to the repeat‐dose RCT where therapeutic efficacy was the primary outcome (measured by time‐to‐next antibiotic treatment) with safety and tolerability being secondary outcome measures (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). The NO trials did not report on exacerbations and there may be little or no difference between NO and placebo in the effect on FEV<sub>1</sub> (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). The addition of two further trials of zinc supplementation since the last update offers no further evidence of a difference between zinc and placebo for our primary outcomes (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). One of these trials found a reduction in the number of days of oral or IV antibiotics needed during the trial period, but the quality of evidence was very low and so we are uncertain if this is a genuine effect (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). It is notable that the need for IV antibiotics did not differ between the two groups, an inconsistency that is difficult to explain. </p> <p>Respiratory function was measured in all of the included trials and no difference between intervention and placebo was found for β‐carotene, garlic, NO or zinc (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>; <a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). The earlier trial of single‐dose KB001‐A reported a non‐significant drop in FEV<sub>1</sub> in the intervention group compared to placebo, where a slight increase in FEV<sub>1</sub> was seen, RR 4.74 (95% CI 0.28 to 79.44) (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). However, in the 16‐week trial of KB001‐A there was a 3% absolute increase from baseline in % predicted FEV<sub>1</sub> at week 16 for the KB001‐A arm versus placebo, MD 3.2% (95% CI 1.12 % to 5.30 %) (P = 0.003) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). The quality of this evidence, however, was deemed to be very low. </p> <p>Few adverse events were seen across all of the different interventions and the adverse events that were reported were mild or not treatment related. QoL was only reported in the trials of KB001‐A where no difference in CFQ‐R was seen between KB001‐A and placebo (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). Sputum microbiology was measured and reported for the trials of KB001‐A and NO. There was very low‐quality evidence of a numerical reduction in <i>P aeruginosa</i> density after KB001‐A, but it was non‐significant (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The trials looking at the effects of NO reported significant reductions in <i>S aureus</i> and near significant reductions in <i>P aeruginosa</i> but the quality of this evidence is very low (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </section> <section id="CD008037-sec-0104"> <h3 class="title" id="CD008037-sec-0104">Overall completeness and applicability of evidence</h3> <p>We are confident that we have identified all the trials that meet our inclusion criteria as our searches were thorough and we contacted authors for extra information where necessary. One of the trials included in the 2013 update was only in abstract form, but the full paper has now been published and included in the 2020 update (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). Not all of the included trials measure our primary outcome (pulmonary exacerbations) and some of those that did used surrogate measures such as days on antibiotics. There is a preponderance to include participants in the younger age group ‐ children and adolescents. Potentially this group of younger individuals, prior to chronic colonisation with multi‐resistant bacteria, could have most to gain from an intervention that might act to reduce infection and hence spare lung function and QoL at an earlier age. However, the generalisability of this approach to the more unwell individuals, who tend not to be included in such trials, is questionable. </p> <p>It should also be noted that since the β‐carotene trial was conducted, larger randomised trials with subsequent analyses have demonstrated an increased risk of development of certain malignancies (lung and stomach) in individuals with lung disease when given a daily 20 mg to 30 mg β‐carotene supplement (<a href="./references#CD008037-bbs2-0045" title="Druesne-PecolloN , Latino-MartelP , NoratT , BarrandonE , BertraisS , GalanP , et al. Beta-carotene supplementation and cancer risk: a systematic review and meta-analysis of randomized controlled trials. International Journal of Cancer2010;127(1):172-84. [DOI: 10.1002/ijc.25008]">Druesne‐Pecollo 2010</a>). The authors believe this precludes further investigation of the high‐dose supplementation regimen investigated in this review. </p> <p>One trial is yet to be completed and published and we await the results of this (<a href="./references#CD008037-bbs2-0042" title="DaviesJ . Oligo G: a novel mucolytic from basic science to clinical trials. Pediatric Pulmonology2017;52 Suppl 47:150-1. [CFGD REGISTER: BD235c] DonaldsonSH , BennettWD , ZemanK , PresslerT , GowL , ConwayJ , et al. A first in class mucus conditioning drug-effect of an inhaled alginate oligosaccharide (oligo-g) on mucus clearance in subjects with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:305. [CFGD REGISTER: BD235d] PresslerT , DonaldsonS , SmerudKT , MyrsetAH , OligoG Study Team. A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 1:S1. [CFDG REGISTER: BD235b] PresslerT , DonaldsonSH , DaviesJC , Hilde MyrsetA . A double-blind, randomised, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) administered for 28 days in subjects with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl:271. [CFGD REGISTER: BD235a] PresslerT . A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984). Clinicaltrials.gov August 2016. ">Pressler 2017</a>). There are six trials which have been completed but which are listed as 'Awaiting assessment' until we have the results we can include and analyse (<a href="./references#CD008037-bbs2-0036" title="DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations. Pediatric Pulmonology2018;53(S2):260. [CENTRAL: CN-01785552] [CFGD REGISTER: PI309a] [EMBASE: 624049687]DevereuxG , BourkeS , DainesC , DoeS , DoughertyR , FrancoR , et al. Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations. Journal of Cystic Fibrosis2019;18(Supplement 1):S23-4. [CENTRAL: CN-02006157] [CFGD REGISTER: PI309b] [EMBASE: 2001976515]">CARE‐CF‐1</a>; <a href="./references#CD008037-bbs2-0037" title="BoskabadyM , Nemat KhorasaniE , MansouriF , SoltanianE , BoskabadyM . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Journal of Research in Medical Sciences2012;17(12):jrms.mui.ac.ir/index.php/jrms/article/view/8833. KhorasaniEN , MansouriF . Effect of zinc supplementation on respiratory infections in children with cystic fibrosis. In: Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria. 2009:722s. [ABSTRACT NO.: P4032] [CENTRAL: 793188] [CFGD REGISTER: GN255] ">Khorasani 2009</a>; <a href="./references#CD008037-bbs2-0038" title="PuvvadiR , MikkelsenH , McCahonL , DitchamW , ReidD , LamontI , et al. EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2019;54:299. [CENTRAL: CN-01990631] [CFGD REGISTER: PI319] [EMBASE: 629388437]">Puvvadi 2019</a>; <a href="./references#CD008037-bbs2-0039" title="EUCTR2014-002125-35-DE. A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE (first received 21 July 2014). NCT02453789. A study of oligog in cystic fibrosis subjects with burkholderia spp. infection. clinicaltrials.gov/show/NCT02453789 (first received 27 May 2015). [CFGD REGISTER: BD223e] RyePD , MahenthiralingamE , WeiserR , MarchesiJR , OpitzP , TrentmannM , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric Pulmonology2015;50 Suppl 41:328. [ABSTRACT NO.: 363] [CENTRAL: 1092173] [CFGD REGISTER: BD223a] WeiserR , MahenthiralinghamE , MarchesiJ , OpitzP , TrentmannM , RyePD , et al. Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial. Journal of Cystic Fibrosis2016;15 Suppl 1:S60, Abstract no: 35. [CENTRAL: 1157480] [CFGD REGISTER: BD223b] WeiserR , MarchesiJ , OpitzP , TrentmannM , RyePD , OnsoyenE , et al. Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP. Pediatric pulmonology2016;51:332. [CFGD REGISTER: BD223c] WeiserR , SmithA , MarchesiJ , RyePD , DessenA , Hilde MyrsetA , et al. Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients. Journal of Cystic Fibrosis2017;16 Suppl 1:S79. [CFGD REGISTER: BD223d] ">Rye 2015</a>; <a href="./references#CD008037-bbs2-0040" title="NCT01465529. A cross-over study of OligoG in subjects with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT01465529 (first posted 04 November 2011). WalshawM , McElvaneyG , WilliamsR , MoriceA , CarrollM , HaworthC , et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]. Journal of Cystic Fibrosis2014;13 Suppl 2:S58, Abstract no: 45. [CENTRAL: 996544] [CFGD REGISTER: BD202] ">Walshaw 2014</a>; Zabner 2009a). </p> </section> <section id="CD008037-sec-0105"> <h3 class="title" id="CD008037-sec-0105">Quality of the evidence</h3> <p>The gradings for the quality of the evidence for each comparison are presented in the summary of findings tables (<a href="./full#CD008037-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008037-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008037-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008037-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD008037-tbl-0005">summary of findings Table 5</a>). </p> <p>The quality of the evidence for this review is limited by the size and quality of the underlying trials and the fact that there were no data to combine in a meta‐analysis. Two of our five comparisons included only one trial (β‐carotene (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>); garlic (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>)), the remaining three comparisons include two trials each (KB001‐A (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>); NO (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>); and zinc (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>)). </p> <p>The quality of the evidence for β‐carotene was low because of concerns around randomisation and allocation concealment as well as the trial having a small sample size and low event rates. We are uncertain whether β‐carotene improves our primary outcomes (<a href="./references#CD008037-bbs2-0005" title="EnglB , RustP , EichlerI , RennerS , ElmadfaI . Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months. Monatsschrift fur Kinderheilkunde1997;145:S 134. [CFGD REGISTER: GN69g] RennerS , RathR , RustP , LehrS , FrischerT , ElmadfaI , et al. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax2001;56(1):48-52. [CFGD REGISTER: GN69f] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. In: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD REGISTER: GN69b] RennerS , WojnarowskiC , KollerDY , RustP , ElmadfaI , EichlerI . Patients with cystic fibrosis (CF) benefit from β-Carotene supplementation for 6 months. Pediatric Pulmonology1997;24(Suppl 15):314. [CFGD REGISTER: GN69a] RustP , EichlerI , ElmadfaI . Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis. Atemwegs und Lungenkrankheiten1997;23:51. [CFGD REGISTER: GN69a] RustP , EichlerI , RennerS , ElmadfaI . Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research1998;68(2):83-7. [CFGD REGISTER: GN69b] RustP , EichlerI , RennerS , ElmadfaI . Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function. Annals of Nutrition and Metabolism2000;44(1):30-7. [CFGD REGISTER: GN69e] [PMID: 10838464]">Renner 2001</a>). </p> <p>Although there was only one trial included in the comparison of garlic with placebo the quality of the trial was deemed to be moderate and only downgraded because of small sample size. However, the trial did not report on our primary outcome of pulmonary exacerbations and there is probably little or or no difference in respiratory function or adverse events (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> <p>There were two trials looking at the effect of KB001‐A, but they were heterogeneous in design, intervention and in the outcomes they reported (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>; <a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The quality of evidence for our primary outcomes was deemed to be very low and we are very uncertain as to whether KB001‐A improves pulmonary exacerbation rates (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). The evidence for one of our secondary outcomes (need for antibiotics) was deemed to be moderate because the trial reporting on this outcome had a larger sample size and fewer concerns around trial design (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> <p>The quality of evidence for NO was deemed to be low or very low due again to small sample sizes, low event rates and risk of bias within the two included trials. We are very uncertain as to the effect of NO on our primary and secondary outcomes (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>; <a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <p>The evidence for zinc supplementation was deemed moderate for pulmonary exacerbations and adverse events, but very low for the remaining outcomes reported. This is because we were unable to combine the data and so the quality reflects the underlying quality of the trials (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>; <a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </section> <section id="CD008037-sec-0106"> <h3 class="title" id="CD008037-sec-0106">Potential biases in the review process</h3> <p>One of the co‐authors of this review is lead investigator of one of the included trials (<a href="./references#CD008037-bbs2-0008" title="SmythA , CifelliP , LewisS , ErskineP , HollandE , WillaimsP , et al. Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):337. [CFGD REGISTER: PI238c] SmythA , CifelliP , LewisS , ErskineP , HollandE , WilliamsP , et al. A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa. Pediatric Pulmonology2008;43(Suppl 31):336. [CFGD REGISTER: PI238b] SmythA . The Garlic Against Pseudomonas (GAP) study [A randomised controlled trial (pilot study) of the use of macerated garlic in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa]. www.isrctn.com/ISRCTN21133397 (first received 01 April 2007). [CFGD REGISTER: PI238a] [DOI: 10.1186/ISRCTN21133397]SmythAR , CifelliPM , OrtoriCA , RighettiK , LewisS , ErskineP , et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomised controlled trial. Pediatric Pulmonology2010;45(4):356-62. [CFGD REGISTER: PI238d] ">Smyth 2010</a>). </p> </section> <section id="CD008037-sec-0107"> <h3 class="title" id="CD008037-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>There have been no previous systematic reviews of antibiotic adjuvant therapies for pulmonary infection in individuals with CF. Reviews of strategies in development stress the pre‐clinical nature of much of these approaches and unfortunately biotechnology companies developing new therapies may defer publication of commercially sensitive results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008037-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008037-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008037-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 1: Days of antibiotic consumption" data-id="CD008037-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 1: Days of antibiotic consumption </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 2: Respiratory function absolute FEV1 % predicted up to 3 months" data-id="CD008037-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 2: Respiratory function absolute FEV<sub>1</sub> % predicted up to 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 3: Mortality" data-id="CD008037-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Chronic infection: β‐carotene supplementation versus placebo, Outcome 3: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 1: Respiratory function (% change FEV1)" data-id="CD008037-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 1: Respiratory function (% change FEV<sub>1</sub>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 2: Mortality" data-id="CD008037-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 2: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 3: Mild adverse events" data-id="CD008037-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Chronic infection: garlic supplementation versus placebo, Outcome 3: Mild adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 1: Pulmonary exacerbations " data-id="CD008037-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 1: Pulmonary exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 2: Decrease in respiratory function (FEV1)" data-id="CD008037-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 2: Decrease in respiratory function (FEV<sub>1</sub>) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 3: Number of participants experiencing an adverse event" data-id="CD008037-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 3: Number of participants experiencing an adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 4: Serious adverse events" data-id="CD008037-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 5: Ear and labyrinth adverse effects" data-id="CD008037-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 5: Ear and labyrinth adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 6: Gastrointestinal adverse events" data-id="CD008037-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 6: Gastrointestinal adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 7: General adverse events" data-id="CD008037-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 7: General adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 8: Infections and infestations" data-id="CD008037-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 8: Infections and infestations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 9: Injury, poisoning and procedural complications  " data-id="CD008037-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 9: Injury, poisoning and procedural complications   </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 10: Investigative adverse events" data-id="CD008037-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 10: Investigative adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 11: Nervous system adverse events" data-id="CD008037-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 11: Nervous system adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 12: Psychiatric adverse events" data-id="CD008037-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 12: Psychiatric adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 13: Respiratory, thoracic and mediastinal adverse events" data-id="CD008037-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 13: Respiratory, thoracic and mediastinal adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 14: Skin and subcutaneous tissue adverse events" data-id="CD008037-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 14: Skin and subcutaneous tissue adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 15: Vascular adverse events" data-id="CD008037-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Chronic infection: KB001‐A versus placebo, Outcome 15: Vascular adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chronic infection: nitric oxide versus placebo, Outcome 1: Change from baseline in FEV1 % predicted" data-id="CD008037-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Chronic infection: nitric oxide versus placebo, Outcome 1: Change from baseline in FEV<sub>1</sub> % predicted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Chronic infection: nitric oxide versus placebo, Outcome 2: Change from baseline in FVC % predicted" data-id="CD008037-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Chronic infection: nitric oxide versus placebo, Outcome 2: Change from baseline in FVC % predicted </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 1: Pulmonary exacerbations (number of participants requiring IV antibiotics)" data-id="CD008037-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 1: Pulmonary exacerbations (number of participants requiring IV antibiotics) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 2: Respiratory function (FVC %predicted)" data-id="CD008037-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 2: Respiratory function (FVC %predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 3: Antibiotic consumption (days oral antibiotics)" data-id="CD008037-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 3: Antibiotic consumption (days oral antibiotics) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 4: Antibiotic consumption (days IV antibiotics)" data-id="CD008037-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 4: Antibiotic consumption (days IV antibiotics) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 5: Antibiotic consumption (days of oral and IV antibiotics)" data-id="CD008037-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 5: Antibiotic consumption (days of oral and IV antibiotics) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 6: Respiratory function (FEV1 % predicted)" data-id="CD008037-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 6: Respiratory function (FEV<sub>1</sub> % predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008037-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/urn:x-wiley:14651858:media:CD008037:CD008037-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 7: Adverse events (number of participants hospitalised in the study period)" data-id="CD008037-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_t/tCD008037-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Chronic infection: zinc supplementation versus placebo, Outcome 7: Adverse events (number of participants hospitalised in the study period) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/media/CDSR/CD008037/image_n/nCD008037-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008037-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: oral β‐carotene supplementation </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>β‐carotene</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Days of antibiotic use</p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of antibiotics was 18.5 days in the control group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of days of antibiotics in the intervention group was <b>8 days lower</b> (18.8 days lower to 2.78 days higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐8.00</b> (‐18.78 to 2.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors of this paper defined pulmonary exacerbations by the number of days of antibiotics. </p> <p>Pulmonary exacerbations were less frequent in the intervention group but this was not statistically significant (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> absolute FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted was 80.9% in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was <b>10.9% lower</b> (32.2% lower to 10.4% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐10.90</b> (‐32.23 to 10.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results favour the placebo for effect on FEV<sub>1</sub> but this was not significant (P = 0.32). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no adverse events reported during the trial. Some participants reported better tanning after exposure to sunlight. No further data were provided for adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>see pulmonary exacerbations</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was reported by the authors as their definition of pulmonary exacerbations. The number of days of antibiotics was less in the β‐carotene group but not significantly so (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD</b> : mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to risk of bias within the included trial, particularly from uncertainty of randomisation method and allocation concealment.<br/><sup>b</sup> Downgraded once due to imprecision. The trial had a small number of participants which is well below the optimal information size and low event rates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings: β‐carotene compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008037-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with <i>P aeruginosa</i> </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: garlic capsule once daily </p> <p><b>Comparison</b>: placebo capsule once daily </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Garlic supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> change from baseline in % predicted FEV<sub>1</sub> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted was ‐3.6 % in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>1.59% higher</b> (7.49% lower to 10.67% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.59</b> (‐7.49 to 10.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the groups after 8 weeks of treatment (P = 0.73). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>mild adverse events</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 participants in the garlic group reported minor adverse effects: diarrhoea: OR 5.87 (95% CI 0.25 to 135.15; P = 0.27); halitosis: OR 5.87 (95% CI 0.25 to 135.15; P = 0.27); abdominal pain: OR 3.24 (95% CI 0.12 to 87.13; P = 0.48); dysuria: OR 3.24 (95% CI 0.12 to 87.13; P = 0.48). </p> <p>1 participant in each group reported minor haemoptysis, OR 1.00 (95% CI 0.06 to 17.90; P = 1.0). </p> <p>Overall there was no significant difference between garlic and placebo for any of the adverse effects. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>days of antibiotic use</p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days of antibiotic use was not reported but 7 participants in the garlic group received intravenous antibiotics compared to 5 in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>MD:</b> mean difference; <b>QoL</b>: quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision from low number of participants which does not reach the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: garlic supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008037-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (12 or over) and adults with cystic fibrosis and lung infection </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: monoclonal antibody KB001‐A </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>KB001‐A</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> <p>Follow‐up: 8 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Of the 2 trials reporting this outcome, the small trial reported no pulmonary exacerbations in the low‐dose group (10 mg/kg), 1 pulmonary exacerbation in the 3 mg/kg group and 2 pulmonary exacerbations in the placebo group (RR 0.25 (95% CI 0.03 to 2.40)). This showed a slight difference in favour of KB001‐A but this was non‐significant (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>The larger Jain trial, did not report exacerbations as an outcome, but did report that exacerbations were the most commonly reported adverse event in both the KB001‐A and placebo group (57.8% of KB001‐A participants and 67.4% of placebo participants) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data from the 2 trials could not be combined as 1 was a single‐dose trial whilst the other trial administered KB001‐A via infusion every 4 weeks over 16 weeks in total. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>number of episodes of a drop in FEV<sub>1</sub> (unit of measurement not given) </p> <p>Follow‐up: 8 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Six participants who received a single 3 mg/kg dose of KB001‐A experienced a decrease in FEV<sub>1</sub>, RR 4.74 (95% CI 0.28 to 79.44) compared to no drop in FEV<sub>1</sub> in the placebo group (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>At the end of the 16‐week trial of KB001‐A, the authors reported a 3 percentage point increase from baseline in % predicted FEV<sub>1</sub>, MD 3.2% (95% CI 1.12% predicted to 5.30% predicted; P = 0.003) in the KB001‐A arm versus placebo (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>number of participants experiencing adverse events</p> <p>Follow up: 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla (single‐dose trial) reported a slight non‐significant difference in how many participants experienced any adverse event favouring placebo, RR 1.30 (95% CI 0.90 to 1.87) and no significant difference between intervention and placebo for serious adverse events: bronchitis (1 participant in the KB001‐A group) RR 1.58 (95% CI 0.07 to 35.32); sinusitis (1 participant in the placebo group) RR 0.18 (95% CI 0.01 to 3.92) (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain reported no treatment‐emergent adverse events and similar numbers of participants with infusion reactions between intervention and placebo groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither of the trials reported significant differences in any adverse events, but event rates were very low. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>time to need for antibiotics</p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Jain found no difference in the time to need for antibiotics in the KB001‐A group versus placebo over the 16‐week trial period, HR 1.00 (95% CI 0.69 to 1.45). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>change in CFQ‐R score</p> <p>Follow‐up: 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla reported no difference in the change in CFQ‐R from baseline between the KB001‐A and placebo groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only the Milla study reported CFQ‐R (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain (n = 169) did not measure CFQ‐R, but did measure change in respiratory symptom scores from baseline using the CFRSD‐CRISS symptom severity score. There was no difference found between treatment groups (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>We were not able to enter the data into the analysis and have reported results narratively (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). At day 28 there was a numerical reduction from baseline in median mucoid <i>P aeruginosa</i> density in the KB001‐A 10 mg/kg group (‐0.4 log<sub>10</sub>) compared to placebo (0.8 log<sub>10</sub>), but the changes were not significant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>e,f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inflammatory markers</b> </p> <p>Follow‐up: 28 to 56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Milla reported no significant change from baseline in any biomarkers but there was a trend towards a KB001‐A dose‐dependent reduction in sputum MPO, IL‐8, IL‐1β and NE (<a href="./references#CD008037-bbs2-0004" title="MillaC , AccursoF , ChmielJ , McCoyK , BillingsJ , AtkinsonJ , et al. A phase I/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine2009;179:A1190. [CFGD REGISTER: PI267d] MillaC , ChmielJ , McCoyKS , AccursoFJ , BillingsJ , BoyleMP , et al. A phase 1/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa. Pediatric Pulmonology2008;43 Suppl 31:341. [ABSTRACT NO.: 392] [CENTRAL: 921645] [CFGD REGISTER: PI267b ] MillaC , ChmielJF , AccursoFJ , McCoyKS , BillingsJL , AtkinsonJJ , et al. Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa. Pediatric Pulmonology2009;44 Suppl 32:341. [ABSTRACT NO.: 369] [CENTRAL: 921646] [CFGD REGISTER: PI267c ] MillaCE , Accurso FJ , ChmielJ , McCoyK , BillingsJ , AtkinsonJJ , et al. Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A1845. [CENTRAL: 758759] [CFGD REGISTER: PI267g] MillaCE , ChmielJF , AccursoFJ , VandevanterDR , KonstanMW , YarrantonG , et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology2014;49(7):650-8. [CENTRAL: 995342] [CFGD REGISTER: PI267e] [EMBASE: 2014431697]NCT00638365. Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa [A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa ]. clinicaltrials.gov/ct2/show/NCT00638365 (first received 19 March 2008). [CFGD REGISTER: PI267a] ">Milla 2013</a>). </p> <p>Jain reported a ‐0.24 log<sub>10</sub> reduction in IL‐8 in the KB001‐A group compared to placebo at week 16 (P = 0.04) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Jain trial also reported a non‐significant decrease in sputum NE, MD ‐0.27 (95% CI ‐0.58 to 0.04; P = 0.084) (<a href="./references#CD008037-bbs2-0003" title="ChmielJ , HamblettNM , GellerD , KonstanM , VanDevanterD , ThompsonV , et al. A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa. Pediatric Pulmonology2015;50 Suppl 41:272. [ABSTRACT NO.: 218] [CENTRAL: 1092183] [CFGD REGISTER: PI287] JainR , BeckettVV , KonstanMW , AccursoFJ , BurnsJL , Mayer-HamblettN , et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2018;17(4):484-91. NCT01695343. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A). www.clinicaltrials.gov/ct2/show/NCT01695343 (first received 27 September 2012). ">Jain 2018</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R</b> : CF Questionnaire‐Revised; <b>CFRSD‐CRISS</b> : Cystic Fibrosis Respiratory Symptom Diary‐Chronic Respiratory Infection Symptom Score; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>HR</b> : hazard ratio; <b>IL‐1β</b> : interleukin‐1β ;<b>IL‐8</b> : interleukin 8; <b>MD</b> : mean difference; <b>MPO</b> : myeloperoxidase; <b>NE</b> : neutrophil elastase; <b><i>P aeruginosa</i> </b><i>: Pseudomonas aeruginosa</i>; <b>QoL</b> : quality of life; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Dowgraded twice due to risk of bias within the trials contributing to this outcome. There was concern around randomisation and allocation concealment in 1 trial and a risk from attrition bias in the other included trial. </p> <p>b. Downgraded due to inconsistency caused by heterogeneity between the 2 studies for his outcome. </p> <p>c. Downgraded due to imprecision from low event rates.</p> <p>d. Downgraded once because there was unclear risk of bias from attrition in the 1 included trial. Although an intention‐to‐treat analysis was used, there was a 27% drop‐out rate </p> <p>e. Downgraded once due to risk of bias within the 1 included trial for this outcome. There was concern around randomisation and allocation concealment as this was not clearly stated. </p> <p>f. Downgraded once due to imprecision caused by low participant numbers and low event rates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: monoclonal antibody KB001‐A compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008037-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (12 or over) and young adults with cystic fibrosis </p> <p><b>Settings</b>: unclear if inpatient or outpatient </p> <p><b>Intervention</b>: inhaled NO (10 ppm inhaled overnight for 5 ‐ 7 days; 20 ppm or 40 ppm inhaled continuously for 44 hours) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>NO</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured in this trial.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>mean change in FEV<sub>1</sub> % predicted from baseline </p> <p>Follow‐up: 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group is 6.17%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was<br/><b>2% lower</b> (10% lower to 6% higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐1.95</b> (‐9.94 to 6.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between the NO group and placebo (P = 0.63).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 48 hours to 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>In one trial 4 participants reported adverse events including epistaxis, cough and cold, increased cough and haemoptysis but all were considered mild and only possibly related to the trial treatment. In the placebo group only one adverse event was reported, which was epistaxis (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> <p>Sagel reported no serious adverse events in either NO or placebo group at either the low dose or high dose of NO (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum microbiology</b> </p> <p>Follow‐up: 48 hours to 20 days</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial showed a significant reduction in <i>S aureus</i> colony counts in the high‐dose NO group relative to placebo (P = 0.03) and a near significant reduction in <i>P aeruginosa</i> colony counts in the high‐dose group relative to placebo (P = 0.06) (<a href="./references#CD008037-bbs2-0006" title="NCT00570349. Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis. www.clinicaltrials.gov/ct2/show/NCT00570349 (first received 10 December 2007). SagelSD , MonchilL , ParkerD , EmmettP , WagnerB , AbmanS . Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study. Pediatric Pulmonology2009;44 Suppl 32:299. [ABSTRACT NO.: 251] [CENTRAL: 921940] [CFGD REGISTER: OV21] ">Sagel 2009</a>). </p> <p>The second trial found a significant reduction in <i>P aeruginosa</i> biofilm aggregates compared with those receiving placebo with antibiotics over the 7‐day treatment period (P = 0.029) and there was less <i>P aeruginosa</i> biofilm in the NO group compared with placebo (<a href="./references#CD008037-bbs2-0002" title="CathieK , HowlinR , BarraudN , CarrollM , ClarkeS , ConnettG , et al. Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial. American Journal of Respiratory and Critical Care Medicine2014;189:A2843. CathieK , HowlinR , CarrollM , ClarkeS , ConnettG , CorneliusV , et al. RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial. Archives of disease in childhood2014;99:A159. HowlinRP , CathieK , Hall-StoodleyL , CorneliusV , DuignanC , AllanRN , et al. Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Molecular Therapy2017;25(9):2104-16. ">Howlin 2017</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>NO</b>: nitric oxide; <i><b>P aeruginosa</b>: Pseudomonas aeruginosa</i>; <b>RR</b>: risk ratio; <i><b>S aureus</b>: Staphylococcus aureus</i>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once from risk of bias because of uncertainty around selective reporting of outcomes.<br/><sup>b</sup> Downgraded once due to imprecision from very low number of participants and low event rates.<br/><sup>c</sup> Downgraded twice for risk of bias within the included trials. There were concerns around randomisation, allocation concealment, selective reporting and attrition bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: nitric oxide compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008037-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: zinc supplementation (30 mg orally once daily) </p> <p><b>Comparison</b>: placebo (orally once daily) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Zinc supplement</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b> number of participants requiring IV antibiotics </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>211 per 1000.</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b><br/>(137 to 1000). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.85</b> (0.65 to 5.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results favour placebo, but not significantly (P = 0.25) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory function</b> </p> <p>mean FEV<sub>1</sub> % predicted </p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial showed no difference between groups, MD ‐5.46 (95% CI ‐19.44 to 8.52) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> <p>A further paper reported that the median (IQR) FEV<sub>1</sub> % predicted value was 8.97% (‐18.23% to 0.33%) lower than baseline in the zinc group and 9.55% (‐9.59% to 12.88%) higher in the placebo group (P = 0.08) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results have been reported narratively as the outcome was reported differently in the 2 trials. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> number of participants hospitalised during the trial </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> (161 to 939). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (0.51 to 2.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All of the serious adverse events were related to exacerbations. Although no data were reported, the Abdulhamid trial reported there were no adverse events (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for antibiotics</b> </p> <p>number of days on IV or oral antibiotics</p> <p>Follow‐up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Abdulhamid reported that significantly fewer oral antibiotics alone were needed by participants in the zinc group, MD ‐17.74 (95% CI ‐26.98 to ‐8.50); but there was no significant difference between groups in the need for IV antibiotics alone, MD 0.52 (95% CI ‐3.07 to 4.11) (<a href="./references#CD008037-bbs2-0001" title="AbdulhamidI , BeckFW , MillardS , ChenX , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2008;43(3):281-7. [CFGD REGISTER: GN111b] [DOI: 10.1002/ppul.20771]AbdulhamidI , MillardS , BeckF , ChenX , Van WagnenC , PrasadA . Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology2005;40 Suppl 28:348. ">Abdulhamid 2008</a>). </p> <p>The Sharma trial found no significant difference in the number of days on IV or oral antibiotics (P = 0.76) (<a href="./references#CD008037-bbs2-0007" title="KabraSK . Effect of zinc supplementation in children with cystic fibrosis. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=3508&amp;EncHid=&amp;userName=zinc (first received 14 December 2011). SharmaG , LodhaR , ShastriS , SainiS , KapilA , SinglaM , et al. Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection. Respiratory Care2016;61(1):78-84. [CFGD REGISTER: GN256] [PMID: 26443019]">Sharma 2016</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sputum microbiology</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Inflammatory markers</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>IV</b> : intravenous; <b>IQR</b> : interquartile range; <b>RR</b> : risk ratio; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded once due to imprecision caused by low event rates and a small participant numbers (n = 37).<br/><sup>b</sup> Downgraded once due to risk of bias within 1 of the included trials; there were concerns across 5 out of the 6 domains for assessing risk of bias.<br/><sup>c</sup> Downgraded once due to imprecision from small number of participants.<br/><sup>d</sup> Downgraded once due to inconsistency caused by heterogeneity between the 2 trial results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Zinc supplementation compared with placebo for chronic pulmonary infection in cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/full#CD008037-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008037-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chronic infection: β‐carotene supplementation versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Days of antibiotic consumption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Over 1 month and up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.00 [‐18.78, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Respiratory function absolute FEV<sub>1</sub> % predicted up to 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Over 1 month and up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.90 [‐32.23, 10.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Over 1 month and up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chronic infection: β‐carotene supplementation versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008037-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chronic infection: garlic supplementation versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Respiratory function (% change FEV<sub>1</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Over 1 month and up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [‐7.49, 10.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Over 1 month and up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mild adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.87 [0.25, 135.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Halitosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.87 [0.25, 135.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.12, 87.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Dysuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [0.12, 87.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Minor haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 17.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chronic infection: garlic supplementation versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008037-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic infection: KB001‐A versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pulmonary exacerbations  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Decrease in respiratory function (FEV<sub>1</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Number of participants experiencing an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.90, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.07, 35.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Ear and labyrinth adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Gastrointestinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Abdominal pain upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Cheilitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.3 Pancreatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.4 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 General adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Chills</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Crepitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.5 Infusion‐related reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.6 Infusion site discolouration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.7 Infusion site rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.8 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.9 Pyrexia (fever)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Infections and infestations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Injury, poisoning and procedural complications   <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Procedural pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Sunburn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Investigative adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Blood pressure increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Abnormal breath sounds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.3 Increased heart rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Nervous system adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.3 Sinus headache </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Psychiatric adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.2 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.3 Stress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Respiratory, thoracic and mediastinal adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 Asthma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.2 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.3 Dysphonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.4 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.5 Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.6 Nasal congestion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.7 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.8 Pharyngolaryngeal pain </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.9 Productive cough </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.10 Rales</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.11 Respiratory tract congestion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.12 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.13 Sinus congestion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.14 Throat irritation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.15 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Skin and subcutaneous tissue adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 Oral pruritus </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.2 Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.3 Urticaria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Vascular adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chronic infection: KB001‐A versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008037-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chronic infection: nitric oxide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Change from baseline in FEV<sub>1</sub> % predicted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.95 [‐9.94, 6.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.95 [‐9.94, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Change from baseline in FVC % predicted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.03 [‐18.50, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Up to 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.03 [‐18.50, 2.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chronic infection: nitric oxide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008037-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chronic infection: zinc supplementation versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Pulmonary exacerbations (number of participants requiring IV antibiotics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.65, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Respiratory function (FVC %predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Up to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Antibiotic consumption (days oral antibiotics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Up to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Antibiotic consumption (days IV antibiotics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Up to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Antibiotic consumption (days of oral and IV antibiotics) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Up to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Respiratory function (FEV<sub>1</sub> % predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Up to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Adverse events (number of participants hospitalised in the study period) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.51, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Up to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.51, 2.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chronic infection: zinc supplementation versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008037.pub4/references#CD008037-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008037.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008037-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008037-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008037-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD008037-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008037-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD008037-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008037-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008037\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008037\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008037\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008037\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008037\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008037.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008037.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008037.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008037.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008037.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725439138"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008037.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725439142"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008037.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7b4288b9f4b8',t:'MTc0MDcyNTQ0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 